EP2102176A2 - Macrocyclic factor viia inhibitors useful as anticoagulants - Google Patents

Macrocyclic factor viia inhibitors useful as anticoagulants

Info

Publication number
EP2102176A2
EP2102176A2 EP07869479A EP07869479A EP2102176A2 EP 2102176 A2 EP2102176 A2 EP 2102176A2 EP 07869479 A EP07869479 A EP 07869479A EP 07869479 A EP07869479 A EP 07869479A EP 2102176 A2 EP2102176 A2 EP 2102176A2
Authority
EP
European Patent Office
Prior art keywords
substituted
alkyl
heterocycle
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07869479A
Other languages
German (de)
English (en)
French (fr)
Inventor
Nicholas Ronald Wurtz
Eldon Scott Priestley
Daniel L. Cheney
Peter W. Glunz
Xiaojun Zhang
Vladimir Ladziata
Brandon Parkhurst
Luciano Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP2102176A2 publication Critical patent/EP2102176A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems

Definitions

  • the present invention provides novel macrocycles, and analogues thereof, which are selective inhibitors of the serine protease coagulation factor Vila.
  • This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
  • Thromboembolic diseases remain the leading cause of death in developed countries despite the availability of anticoagulants such as warfarin (Coumadin ® ), heparin, low molecular weight heparins (LMWH), and synthetic pentasaccharides and antiplatelet agents such as aspirin and clopidogrel (Plavix ® ).
  • warfarin Coumadin ®
  • heparin heparin
  • LMWH low molecular weight heparins
  • synthetic pentasaccharides and antiplatelet agents such as aspirin and clopidogrel (Plavix ® ).
  • the oral anticoagulant warfarin inhibits the post-translational maturation of coagulation factors VII, IX, X and prothrombin, and has proven effective in both venous and arterial thrombosis.
  • its usage is limited due to its narrow therapeutic index, slow onset of therapeutic effect, numerous dietary and drug interactions, and a need for monitoring and
  • Factor VII is a plasma serine protease involved in the initiation of the coagulation cascade. It is present in human blood at a concentration of approximately 500 ng/mL, with about 1% of the total amount in the proteolytically active form factor Vila (Morrissey, J. H. et al. Blood 1993, 81, 734- 744).
  • Tissue factor is normally expressed in cells surrounding the vasculature, and is exposed to factor Vila in blood by vessel injury or atherosclerotic plaque rupture. Once formed, the tissue factor/factor Vila complex initiates blood coagulation by proteolytic cleavage of factor X to factor Xa, factor IX to factor IXa and autoactivation of additional factor VII to Vila.
  • Factor Xa generated either directly by tissue factor/factor Vila or indirectly through action of factor IXa, catalyzes the conversion of prothrombin to thrombin.
  • Thrombin converts fibrinogen to fibrin, which polymerizes to form the structural framework of a blood clot, and activates platelets, which are a key cellular component of coagulation (Hoffman, M. Blood Reviews 2003, 17, S1-S5).
  • tissue factor is present in blood, likely in an encrypted form that is de-encrypted during clot formation. (Giesen, P. L. A. et al. Proc. Natl. Acad. ScL 1999, 96, 2311-2315; Himber, J.
  • tissue factor/factor Vila complex derived from blood borne tissue factor may play an important role in propagation of the coagulation cascade (clot growth) and in thrombus formation in the absence of vessel wall injury (i.e., stasis induced deep vein thrombosis or sepsis).
  • the source of blood borne tissue factor is an area of active research (Morrissey, J. H. J. Thromb. Haemost. 2003, 1, 878-880). Therefore, factor Vila plays a key role in propagating this amplification loop and is thus an attractive target for anti-thrombotic therapy.
  • the present invention provides novel macrocycles, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes, especially factor Vila, including stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides processes and intermediates for making the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides a method for the treatment or prophylaxis of a thromboembolic disorder comprising administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for use in therapy.
  • the present invention also provides the use of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the manufacture of a medicament for the treatment or prophylaxis of a thromboembolic disorder.
  • the present invention provides, inter alia, a compound of Formula (I):
  • ring A is phenyl or a pyridyl isomer defined by replacing one of CR 1 , CR 2 , CR 3 , or CR 4 in ring A of formula (I) with N
  • ring B is phenyl or a pyridyl isomer defined by replacing one of CR 8 , CR 9 , CR 10 , or CR 1 1 in ring B of formula (I) with N;
  • Z 1 is C or N
  • Z 2 is C or N; provided that when Z 1 is N, then Z 2 is C; or Z 2 is N, then Z 1 is C; for the definition of Z 3 , as they are written from left to right, the atom connectivity is in the order -NH-Z 3 -Z 2 -;
  • Z 4 is C(O), CR 20 R 20 or SO 2 ;
  • ring D including the two atoms Z 1 and Z 2 which are fused to ring C, is phenyl substituted with 0-3 R 21 or a 5-6 membered heteroaryl consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S, wherein said heteroaryl is substituted with 0-3 R 21 ; for the definitions of L and M, as they are written from left to right, the atom connectivity is in the order (ring A)-L-M-(ring B);
  • M is -CONH-, -SO 2 NH-, -NHCO-, or -NHSO 2 -; when M is -CONH-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-,
  • W is NR h , O or S
  • X is O, S(O) p , or NR 16 ;
  • Y is O or NR 16a ;
  • R 1 is H, F, Cl, Br, I, C 1-4 alkyl substituted with 0-1 OH, C 1-4 fluoroalkyl,
  • R 2 is H, F, Cl, Br, I, -(CH 2 ) s OR a , -(CH 2 ) s SR b , -(CH 2 ) S CF 3 , -(CH 2 ) S OCF 3 , -(CH 2 ) S OCHF 2 , -(CH 2 ) S OCH 2 F, -(CH 2 ) S CN, -(CH 2 ) S NO 2 , -(CH 2 ) s NR C R d -(CH 2 ) s C(O)Ra, -(CH 2 ) s CO 2 R a , -(CH 2 ) s NRcC(O)Ra -(CH 2 ) s C(O)NRcR d -(CH 2 ) s NR c C(0)0R b , -(CH 2 ) s OC(O)OR b , -(CH 2 ) s NR c
  • R 3 is H, F, Cl, Br, I, -(CH 2 ) s OR a , -(CH 2 ) s SR b , -(CH 2 ) S CF 3 , -(CH 2 ) S OCF 3 , -(CH 2 ) S OCHF 2 , -(CH 2 ) S OCH 2 F, -(CH 2 ) S CN, -(CH 2 ) S NO 2 , -(CH 2 ) s NR C R d -(CH 2 ) s C(O)R a , -(CH 2 ) s CO 2 R a , -(CH 2 ) s NRcC(O)R a , -(CH 2 ) s C(O)NR C R d -(CH 2 ) s NR c C(O)OR b , -(CH 2 ) s OC(O)OR b , -(CH 2 )
  • R 4 is H, F, Cl, Br, I, or C 1-4 alkyl
  • R 5 is H, -(CH 2 ) q OR a , -(CH 2 ) q SR b , -(CH 2 ) r CF 3 , -(CH 2 ) q OCF 3 , -(CH 2 ) q OCHF 2 , -(CH 2 ) q OCH 2 F, -(CH 2 ) q CN, -(CH 2 ) q NO 2 , -(CH 2 ) NR c R d , -(CH 2 ) s C(O)R a , -(CH 2 ) s CO 2 R a , -(CH 2 ) q NRcC(O)R a , -(CH 2 ) s C(O)NRcR d -(CH 2 ) q NR c C(O)OR b , -(CH 2 ) q OC(O)OR b , -(CH 2 )
  • R 6 is H, -(CH 2 ) r OR a , -(CH 2 ) r SR b , -(CH 2 ) S CF 3 , -(CH 2 ) r OCF 3 ,
  • R 7 is H or C 1-6 alkyl; alternatively, R 6 and R 7 can be joined to form a 3-7 membered carbocycle or heterocycle; wherein said carbocycle may be substituted with 0-2 R fl ; and said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 RS 1 ;
  • R 8 is H, F, Cl, Br, CN, CH 2 F, CHF 2 , -(CH 2 ) S CF 3 , -(CH 2 ) S CN, -(CH 2 ) S NO 2 , Ci_ 6 alkyl, C 2 . 6 alkenyl, C 2 .
  • R 12 and R 13 are, independently at each occurrence, F, Cl, OR a , SR b , CF 3 , OCF 3 , OCHF 2 , OCH 2 F, CN, NO 2 , -NR c R d , -C(O)R a , -CO 2 R a , -NR c C(O)R a , -C(O)NR c R d -NR c C(O)OR b , -NR c C(0)NR c R d -OC(O)NR c R d -OC(O)OR a , -SO 2 NR C Rd -NR c SO 2 NR c R d -NR c SO 2 R b , -NR C SO 2 CF 3 , -SO 2 CF 3 , -S(O) 2 R b , Ci -6 alkyl substituted with 0-2 R e , C 2-4 alkenyl substitute
  • R 16 is, independently at each occurrence, H, Cj_ 6 alkyl, C 3-6 cycloalkyl, phenyl, benzyl, -C(O)R a , -C(O)NR c R d , -C(O)OR b , -CH 2 C(O)OR b , -SO 2 NR c R d , -SO 2 CF 3 , -S(O) 2 R b , or -(CH 2 ) s -(5- to 6-membered heterocycle); wherein said alkyl or cycloalkyl are optionally substituted with 0-2 R e , said phenyl and benzyl are optionally substituted with 0-2 R f , and said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 Rg;
  • R 16a is, independently at each occurrence, H, Cj_ 6 alkyl, C 3-6 cycloalkyl, phenyl, benzyl, -C(O)R a , -C(O)NR c R d -C(O)OR b , -CH 2 C(O)OR b , -SO 2 NR c R d -SO 2 CF 3 , -S(O) 2 R b , or 5- to 6-membered heterocycle; wherein said alkyl or cycloalkyl are optionally substituted with 0-2 R e , said phenyl and benzyl are optionally substituted with 0-2 R f , and said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 Rg;
  • R 17 is, independently at each occurrence, H or Me;
  • R 18 is, independently at each occurrence, H, F, Cl, Br, I, CF 3 , OCF 3 , OCHF 2 , OCH 2 F, CN, C i-4 alkoxy, C ⁇ .4 haloalkyl, C 1.4 alkyl, C 2 .4 alkenyl, C 2 .4 alkynyl, or C3-6 cycloalkyl;
  • R 19 is, independently at each occurrence, is, independently at each occurrence, H, C ⁇ _ 4 alkyl, C 2- 4 alkenyl, or C 2 .4 alkynyl;
  • R 20 is, independently at each occurrence, H, CF 3 , Ci_6 alkyl substituted with 0-2 R e , C 1-4 haloalkyl, C 2-4 alkenyl substituted with 0-2 R e , C 2-4 alkynyl substituted with 0-2 R e , or -(CH 2 ) s -(5- to 6-membered heterocycle); wherein said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 Rg l ;
  • R 21 is, independently at each occurrence, F, Cl, Br, I, CN, OH, CF 3 , Ci -4 alkyl, Ci -4 haloalkyl, Ci -4 alkoxy, or C 3 _6 cycloalkyl;
  • R a is, independently at each occurrence, H, C ⁇ .4 alkyl, C 3 .5 cycloalkyl, fluoroalkyl, phenyl, or benzyl; wherein said alkyl and cycloalkyl are optionally substituted with
  • R b is, independently at each occurrence, Ci_ 4 alkyl, C 3 . ⁇ cycloalkyl, fluoroalkyl, phenyl, or benzyl; wherein said alkyl and cycloalkyl are optionally substituted with 0-2 R e , and said phenyl and benzyl are optionally substituted with 0-2 R f ;
  • R c and R ⁇ are, independently at each occurrence, H, C ⁇ .4 alkyl, C 3 _6 cycloalkyl, fluoroalkyl, phenyl, or benzyl; alternatively, R c and R d , when attached to the same nitrogen atom, combine to form a 4- to 7-membered heterocycle comprising: carbon atoms and 0-2 additional heteroatoms selected from N, O, and S(O ) p ; wherein said heterocycle is substituted with 0-2 Rg;
  • R e is, independently at each occurrence, F, CF 3 , OH, or C 1.3 alkoxy
  • R f is, independently at each occurrence, F, Cl, Br, CF 3 , OH, C 1.3 alkyl, or C 1.3 alkoxy;
  • R fl is, independently at each occurrence, R f , -C ⁇ 2R a , -C(O)NR c R d , -CONHSO 2 R b , or -CH 2 CONHSO 2 R b ;
  • RS 1 is, independently at each occurrence, Rg, -CO 2 R* 1 , -C(0)NR c R d ,
  • R h is, independently at each occurrence, H or C ⁇ _ 3 alkyl
  • R 1 is, independently at each occurrence, H, C1.4 alkyl, C3.6 cycloalkyl, phenyl, or benzyl; wherein said alkyl and cycloalkyl are optionally substituted with 0-2 R k and 0-5 F; and said phenyl and benzyl are optionally substituted with 0-2 R f ;
  • RJ is, independently at each occurrence, C ⁇ 4 alkyl, C3.6 cycloalkyl, phenyl, or benzyl; wherein said alkyl and cycloalkyl are optionally substituted with 0-2 R k and 0-5 F, and said phenyl and benzyl are optionally substituted with 0-2 R f ;
  • R k is, independently at each occurrence, CF3, OH, or C ⁇ _ 3 alkoxy;
  • n, at each occurrence, is selected from 0, 1, 2, 3, and 4;
  • p at each occurrence, is selected from 0, 1, and 2;
  • q at each occurrence is selected from 2 or 3;
  • r at each occurrence is selected from 1, 2, or 3; and s, at each occurrence, is selected from 0, 1, and 2.
  • the present invention includes the compounds of
  • the present invention includes the compounds of
  • the present invention includes the compounds of
  • M is -CONH-, -SO 2 NH-, -NHCO-, or -NHSO 2 -; when M is -CONH-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )-, -C(R 12 R 13 )Y-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )XC(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )Y-, -XC(R 12 R 13 )Y-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )C
  • L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, and -C(R 12 R 13 )XC(R 12 R 13 )C(R 12 R 13 )-; when M is -NHCO-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13
  • X is O, S, or NR 16 ;
  • W is NH or O
  • R 2 is H, F, Cl, Br, I, 0R a , SR b , CF 3 , OCF 3 , OCHF 2 , OCH 2 F, CN, NO 2 ,
  • R 3 is H, F, Cl, Br, I, 0R a , SR b , CF 3 , OCF 3 , OCHF 2 , OCH 2 F, CN, NO 2 , -NRCRd, -C(O)Ra, -CO 2 Ra, -NRcC(0)R a , -C(O)NR c Rd, -NR c C(0)0R b , -NRcC(O)NRCRd, -0C(0)NR c Rd, -SO 2 NRcRd, -NRcSO 2 NRcRd, -NR c SO 2 R b , -NR C SO 2 CF 3 , -SO 2 CF 3 , -S(O) 2 R b , -O(CH 2 ) n CO 2 R a , -SO 2 NHCOR b , -CONHSO 2 R b , C i-6 alkyl substituted with 0-2 R
  • R 5 is H, -CH 2 CH 2 OR a , -CH 2 CH 2 CH 2 ORa -CH 2 CO 2 Ra -CH 2 CH 2 CO 2 Ra, -CH 2 CH 2 CH 2 CO 2 Ra, -CH 2 CH 2 NHCO 2 R b , -CH 2 CH 2 NR c R d , -CH 2 C(0)NR c R d , -CH 2 CH 2 C(O)NR c R d , -CH 2 CONHSO 2 R b , -CH 2 CH 2 CONHSO 2 R b , C 1-6 alkyl substituted with 0-2 R e , -(CH 2 ) S -C 3 .
  • R 6 is H, -CH 2 ORa, -CH 2 CH 2 ORa, CN, -CO 2 R a , -C(O)NR c Rd, -CH 2 CO 2 Ra, -CH 2 C(O)NR C Rd, -CONHSO 2 R b , -CH 2 CONHSO 2 R b , C 1-6 alkyl substituted with 0-2 R e , -(CH 2 ) S -C 3 .
  • R 6 carbocycle substituted with 0-2 R f , or -(CH 2 ) s -5- to 6-membered heterocycle; wherein said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(0) p and is substituted with 0-2 Rg; alternatively, R 5 and R 6 can be joined to form a 2 to 5-membered alkylene chain, which may be substituted with 0- 1 R fl ; R 7 is H or C 1-6 alkyl; alternatively, R 6 and R 7 can be joined to form a 3-7 membered carbocycle or heterocycle; wherein said carbocycle may be substituted with 0-2 RfI ; and said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 Rg 1 ; R 9 is H, F, Cl, Br, I, C 1-4 alkyl, or C 1-4 alkoxy;
  • R 10 and R 11 are, independently at each occurrence, H, F, Cl, Br, I, or C 1-4 alkyl;
  • R 12 and R 13 are, independently at each occurrence, F, Cl, OR a , SR b , CF 3 , OCF 3 , OCHF 2 , OCH 2 F, CN, NO 2 , -NR c Rd -C(O)R a , -CO 2 R a , -NR c C(0)R a , -C(O)NR c R d , -NR c C(O)OR b , -NR c C(O)NR c R d , -OC(O)NR c R d , -SO 2 NR c R d , -NR c SO 2 NR c R d -NR c SO 2 R b , -NR C SO 2 CF 3 , -SO 2 CF 3 , -S(O) 2 R b , Ci -6 alkyl substituted with 0-2 R e , C 2-4 alkenyl substituted with 0
  • the present invention includes the compounds of
  • ring A is phenyl or a pyridyl isomer defined by replacing one of CR 1 , CR 2 , CR 3 , or CR 4 in ring A of formula (I) with N
  • ring B is phenyl or a pyridyl isomer defined by replacing one of CR 8 , CR 9 , CR 10 , or CR 1 1 in ring B of formula (I) with N; with the proviso that when ring A is pyridyl, then ring B is not pyridyl;
  • M is -CONH-, -SO 2 NH-, -NHCO-, or -NHSO 2 -; when M is -CONH-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )-, -C(R 12 R 13 )Y-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )XC(R 12 R 13 )-, XC(R 12 R 13 )Y-, and -C(R 12 R 13 )C(R 12 R 13 )Y-; when M is -SO 2 NH-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13
  • W is NH or O
  • R 4 is H or F.
  • the present invention includes the compounds of
  • M is -CONH- or -NHSO 2 -; when M is -CONH-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )-, -C(R 12 R 13 )Y-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )XC(R 12 R 13 )-, and -C(R 12 R 13 )C(R 12 R 13 )Y-; when M is -NHSO 2 -, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, and -XC(R 12 R 13 )C(R 12 R 13 )-;
  • ring D is optionally substituted with 0-1 F; W is NH;
  • R 1 is H, Cl, Br, methyl, ethyl, 1 -hydroxy ethyl, propyl, isopropyl, vinyl, allyl, 2-propenyl, ethynyl, 1-propynyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, or cyclopentyl;
  • R 2 is H, F, Cl, OR a , Ci .6 alkyl substituted with 0-2 R e , C2-4 alkenyl substituted with 0-2 R e , C2-4 alkynyl substituted with 0-2 R e , or -O-(5- to 6- membered heterocycle); wherein said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 Rg;
  • R 3 is H, F, Cl, OR a , -O(CH 2 ) n CO 2 R a , Ci -6 alkyl substituted with 0-2 R e , C2-4 alkenyl substituted with 0-2 R e , C2-4 alkynyl substituted with 0-2 R e , or -O(benzyl substituted with CO 2 Ra);
  • R 4 is H
  • R 5 is H, C M alkyl, -CH 2 CH 2 OR a , -CH 2 CH 2 CH 2 OR a , -CH 2 CO 2 R a , -CH 2 CH 2 CO 2 R a , -CH 2 CH 2 CH 2 CO 2 Ra -CH 2 CH 2 NHCO 2 Rb, -CH 2 CH 2 NR c R d , -CH 2 C(O)NR c R d , or -CH 2 CH 2 C(O)NR c R d ;
  • R 6 is H, -CH 2 ORa, -CH 2 CH 2 ORa, CN, C M alkyl, -CO 2 R a , -C(0)NR c R d ,
  • R 7 is H
  • R 8 is H, F, Cl, Br, CN, CH 2 F, CHF 2 , -(CH 2 ) S CF 3 , C 1-6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, -(CH 2 VORS -(CH 2 VSRJ, -(CH 2 ) n -NRcRd -(CH 2 ) s CO 2 Ra, -(CH 2 ) s NR c C(0)R a , -(CH 2 ) s CONR c Rd -(CH 2 ) S SO 2 RJ, -(CH 2 ) s SO 2 NR c Rd
  • R9, RlO and Rl 1 are, independently at each occurrence, H, F, or Cl.
  • the present invention includes the compounds of
  • M is -CONH-
  • L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )-, -C(R 12 R 13 )Y-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )XC(R 12 R 13 )-, and -C(R 12 R 13 )C(R 12 R 13 )Y-;
  • W is NH;
  • R 1 is H, Cl, Br, methyl, ethyl, vinyl, 2-propenyl, allyl, ethynyl, 1-propynyl, methoxy, ethoxy, or cyclopropyl;
  • R 8 is H, F, Cl, Br, CN, -(CH 2 VORi, -(CH 2 VSRJ, -(CH 2 ) n -NR c R d , NR c C(0)R a , CONR C Rd -(CH 2 ) S SO 2 RJ, -(CH 2 ) s SO 2 NR c R d , NR C SO 2 RJ, NRcSO 2 CF 3 , -SO 2 CF 3 , -O(benzyl substituted with CO 2 R a ), Ci -6 alkyl substituted with 0-3 R e , C 1-4 fluoroalkyl, C 2-4 alkenyl substituted with 0-3 R e , C 2-4 alkynyl substituted with 0-3 R e , -(CH 2 ) s -C 3- 6 carbocycle substituted with 0-3 R fl , -(CH 2 ) n -5-to 10-membered
  • the present invention includes the compounds of
  • L is selected from -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-,
  • Y is O or NMe
  • R 1 is H, Cl, Br, methyl, ethyl, vinyl, 2-propenyl, ethynyl, methoxy, or ethoxy;
  • R 3 is H, F, Cl, Me, OCH 2 CO 2 H;
  • R 5 is H, C 1 .4 alkyl, -CH 2 CH 2 OR a , -CH 2 CO 2 R a , -CH 2 CH 2 CO 2 R a , -CH 2 CH 2 CH 2 CO 2 R a , -CH 2 CH 2 NHCO 2 R b , -CH 2 NR c R d , -CH 2 C(0)NR c R d , or -CH 2 CH 2 C(O)NR c R d ;
  • R 6 is H, C M alkyl, -C0 2 R a -C(O)NRcRd -CH 2 CO 2 R a , or -CH 2 C(O)NRcRd;
  • R 12 and R 13 are, independently at each occurrence, H, methyl, ethyl, propyl, isopropyl, cyclopropyl, t-butyl, methoxy, ethoxy, propoxy, isopropoxy, cyclopropoxy, OH, CH 2 OH, OCH 2 OMe, or NHCO 2 Bn, with the proviso that no more than two of
  • R 12 and R 13 in L are other than H
  • R 16 is H, C M alkyl, -C(0)R a , -C(0)NR c Rd -C(0)0R b , -CH 2 C(0)0R b , or
  • the present invention includes the compounds of
  • R 1 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy
  • R 2 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy
  • R 3 is H or F
  • R 5 is H, C 1 .4 alkyl, -CH 2 CH 2 OR a , -CH 2 CO 2 R a , -CH 2 CH 2 CO 2 R a , -CH 2 CH 2 CH 2 CO 2 Ra, -CH 2 CH 2 NHCO 2 Rb, -CH 2 CH 2 NR c R d , -CH 2 C(0)NR c R d , or -CH 2 CH 2 C(O)NR c R d ;
  • R 6 is H, methyl, ethyl, -CO 2 H or -CH 2 CO 2 H;
  • R 7 is H
  • R 8 is H, F, Cl, Br, CN, C 1-6 alkyl substituted with 0-3 Re, OR 1 , -CH 2 OR 1 , -C0NR c R d , -SO 2 RJ, -SO 2 NR c R d , phenyl, O-phenyl, a 5 -to 10-membered heterocycle selected from: morpholinyl, pyrrolidinyl, piperidinyl, pyrazolyl, oxazolyl, isoxazolyl,
  • thiazolyl imidazolyl, pyridyl, dihydroisoquiinnoolliinyl, , or 0-5- to -10-membered heterocycle selected from: imidazolyl , oxadiazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, thiadiazolyl, thiazolyl, thiophenyl, or triazolyl wherein said phenyl and heterocycle are substituted with 0-2 Rg; and
  • R 9 , R 10 and R 1 1 are, independently at each occurrence, H, F, or Cl.
  • the present invention includes the compounds of
  • M is -CONH-
  • L is -CH 2 CH 2 CH 2 -, -CH(Me)CH 2 CH 2 -, -CH 2 CH 2 O-, -CHFCH 2 O-, -CH(Me)CH 2 O-, -CH(Et)CH 2 O-, -, -CH(OH)CH 2 O-, -CH(OMe)CH 2 O-, -CH(OEt)CH 2 O-, -CH(CH 2 OH)CH 2 O-, -CH(OCH 2 OMe)CH 2 O-, -CH(NHCO 2 Bn)CH 2 O-, -CH(Me)CH 2 NH-, -CH(Me)CH 2 N(Me)-, -CH 2 N(Me)-, -CH 2 NHCH 2 -, -CH 2 N(Me)CH 2 -, -CH 2 N(Et)CH 2 -, -CH 2 N(Pr)CH 2 -, -CH 2 N(Z-P
  • R 1 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy;
  • R 2 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy;
  • R 3 is H or F
  • R 4 is H
  • R 5 is H, methyl, ethyl, propyl, -CH 2 CO 2 H, -CH 2 CH 2 CO 2 H, -CH 2 CH 2 CO 2 Et, -CH 2 CH 2 CH 2 CO 2 H, -CH 2 CH 2 NHCO 2 Me, -CH 2 CH 2 NHCO 2 ( ⁇ -Bu), -CH 2 CH 2 OH, -CH 2 CH 2 OMe, -CH 2 CH 2 NH 2 , -CH 2 CH 2 CONH 2 , or -CH 2 CH 2 CONHMe;
  • R 6 is H, methyl, ethyl, -CO 2 H or -CH 2 CO 2 H;
  • R 7 is H
  • R 8 is H, F, Cl, Br, CN, OH, -CH 2 OH, -CH 2 OMe, -OCF 2 H, -OCF 3 , -OCF 2 CF 2 H, CO 2 H, -SO 2 Et, -SO 2 (Z-Pr), -SO 2 -cyclopropyl, phenyl, 2-OCF 3 -phenyl, 3-CO 2 H-phenyl, 3-CO 2 Me-phenyl, 2,6-diF-phenyl, 2-F-5-CO 2 H-phenyl, lH-pyrazol-1-yl, l-Me-lH-pyrazol-4-yl, l-Me-lH-pyrazol-5-yl, l-Et-lH-pyrazol-5-yl, oxazol-2-yl, 3,5-diMe-isoxazol-4-yl, 2-thiazolyl, lH-imidazol-1-yl,
  • the present invention includes a compound of
  • the present invention provides a compound selected from one or more exemplified Examples or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention includes a compound of
  • R 1 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy
  • R 2 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy;
  • R 3 is H
  • R 4 is H
  • R 5 is H, methyl, ethyl, or -CH 2 CO 2 H;
  • R 6 is H, methyl, ethyl, -CO 2 H or -CH 2 CO 2 H;
  • R 7 is H;
  • R 8 is -C0NR c R d or -SO 2 R b .
  • ring A is phenyl or a pyridyl isomer defined by replacing one of CR 1 , CR 2 , CR 3 , or CR 4 in ring A of formula (I) with N; and ring B is phenyl.
  • ring A is phenyl and ring B is phenyl.
  • M is -CONH- or -NHSO2-; when M is -CONH-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -XC(R 12 R 13 )-, -C(R 12 R 13 )Y-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )XC(R 12 R 13 )-, and -C(R 12 R 13 )C(R 12 R 13 )Y-; when M is -NHSO2-, L is selected from -C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, and -XC(R 12 R 13 )C(R 12 R 13 )-.
  • M is -CONH-; and L is selected from
  • L is selected from -C(R 12 R 13 )C(R 12 R 13 )C(R 12 R 13 )-, -C(R 12 R 13 )NR 16 C(R 12 R 13 )-,
  • L is -C(R 12 R 13 )C(R 12 R 13 )CH 2 -, -C(R 12 R 13 )C(R 12 R 13 )O-, -C(R 12 R 13 )NR 16 C(R 12 R 13 )-, -C(R 12 R 13 )C(R 12 R 13 )NH-,
  • L is -CH 2 CH 2 CH 2 -, -CH(Me)CH 2 CH 2 -, -CH 2 CH 2 O-, -CHFCH 2 O-, -CH(Me)CH 2 O-, -CH(Et)CH 2 O-, -CH(OMe)CH 2 O-, -CH(OEt)CH 2 O-, -CH(OCH 2 OMe)CH 2 O-, -CH(NHCO 2 Bn)CH 2 O-, -CH(Me)CH 2 NH-, -CH(Me)CH 2 N(Me)-, -CH 2 N(Me)-, -CH 2 NHCH 2 -, -CH 2 N(Me)-, -CH 2 N(Me)-, -CH 2 NHCH 2 -, -CH 2 N(M
  • R 1 is H, Cl, Br, methyl, ethyl, 1 -hydroxy ethyl, propyl, isopropyl, vinyl, allyl, 2-propenyl, ethynyl, 1-propynyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, or cyclopentyl.
  • R 1 is H, Cl, Br, methyl, ethyl, vinyl, 2-propenyl, allyl, ethynyl, 1-propynyl, methoxy, ethoxy, or cyclopropyl.
  • R 1 is H, Cl, Br, methyl, ethyl, vinyl, 2-propenyl, ethynyl, methoxy, or ethoxy.
  • R 1 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy.
  • R 2 is H, F, Cl, OR a , Ci-6 alkyl substituted with 0-2 R e , C2-4 alkenyl substituted with 0-2 R e , C2-4 alkynyl substituted with 0-2 R e , or -O-(5- to 6-membered heterocycle); wherein said heterocycle comprises carbon atoms and 1-3 heteroatoms selected from N, NR C , O, and S(O) p and is substituted with 0-2 Rg.
  • R 2 is H, Cl, Br, methyl, ethyl, methoxy, or ethoxy.
  • R 3 is H, F, Cl, OR a , -O(CH 2 ) n CO 2 R a ,
  • R 3 is H, F, Cl, Me, OCH 2 CO 2 H.
  • R 3 is H or F.
  • R 3 is H.
  • R 4 is H.
  • R 5 is H, -CH 2 CH 2 OR a , -CH 2 CH 2 CH 2 OR a ,
  • -CH 2 CO 2 R a -CH 2 CH 2 CO 2 Ra -CH 2 CH 2 CH 2 CO 2 Ra -CH 2 CH 2 NHCO 2 Rb, -CH 2 CH 2 NR c R d , -CH 2 C(O)NR c R d , -CH 2 CH 2 C(O)NR c Rd, -CH 2 CONHSO 2 R b , -CH 2 CH 2 CONHSO 2 R b , C 1-6 alkyl substituted with 0-2 Re, -(CH 2 ) S -C 3 .
  • R 5 is H, C 1-4 alkyl, -CH 2 CH 2 ORa -CH 2 CH 2 CH 2 ORa -CH 2 CO 2 Ra -CH 2 CH 2 CO 2 Ra -CH 2 CH 2 CH 2 CO 2 Ra, -CH 2 CH 2 NHCO 2 R b , -CH 2 CH 2 NR c Rd -CH 2 C(O)NR c Rd or -CH 2 CH 2 C(O)NR C Rd.
  • R 5 is H, C M alkyl, -CH 2 CH 2 ORa, -CH 2 CO 2 Ra, -CH 2 CH 2 CO 2 Ra 1 -CH 2 CH 2 CH 2 CO 2 Ra, -CH 2 CH 2 NHCO 2 Rb, -CH 2 NR c Rd -CH 2 C(O)NRcRd, or -CH 2 CH 2 C(O)NRcRd.
  • R 5 is H, methyl, ethyl, propyl, -CH 2 CO 2 H, -CH 2 CH 2 CO 2 H, -CH 2 CH 2 CO 2 Et, -CH 2 CH 2 CH 2 CO 2 H, -CH 2 CH 2 NHCO 2 Me, -CH 2 CH 2 NHCO 2 (J-Bu), -CH 2 CH 2 OH, -CH 2 CH 2 OMe, -CH 2 CH 2 NH 2 , -CH 2 CH 2 CONH 2 , or -CH 2 CH 2 CONHMe.
  • R 6 is H, -CH 2 0R a , -CH 2 CH 2 OR a , CN,
  • R 6 is H, -CH 2 0R a , -CH 2 CH 2 OR a , CN, C M alkyl, -CO 2 R a , -C(0)NR c R d , -CH 2 CO 2 R a , or -CH 2 C(0)NR c R d .
  • R 6 is H, C M alkyl, -CO 2 R a , -C(O)NR c Rd, -CH 2 CO 2 R a , or -CH 2 C(O)NRcRd.
  • R 6 is H, methyl, ethyl, -CO 2 H or -CH 2 CO 2 H.
  • R 6 is H, -CH 2 0R a , -CH 2 CH 2 OR a , CN,
  • R 6 is H, -CH 2 0R a , -CH 2 CH 2 ORa CN, C 1.4 alkyl, -C0 2 R a , -C(0)NR c Rd -CH 2 CO 2 Ra, or -CH 2 C(O)NRCRd.
  • R 6 is H, C M alkyl, -C0 2 R a , -C(0)NR c Rd -CH 2 CO 2 Ra, or -CH 2 C(O)NR C Rd.
  • R 6 is H, methyl, ethyl, -CO 2 H or -CH 2 CO 2 H.
  • R 7 is H.
  • R 8 is H, F, Cl, Br, CN, C 1-6 alkyl substituted with 0-3 Re, ORi, -CH 2 ORi, -CONR c Rd, -SO 2 Ri, -SO 2 NRcRd phenyl, O-phenyl, a 5-to 10-membered heterocycle selected from: morpholinyl, pyrrolidinyl, piperidinyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridyl, dihydroisoquinolinyl,
  • R 8 is H, F, Cl, Br, CN, OH, -CH 2 OH, -CH 2 OMe, -OCF 2 H, -OCF 3 , -OCF 2 CF 2 H, CO 2 H, -SO 2 Et, -SO 2 (Z-Pr), -SO 2 -cyclopropyl, phenyl, 2-OCF 3 -phenyl, 3-CO 2 H-phenyl, 3-CO 2 Me-phenyl, 2,6-diF-phenyl, 2-F-5-CO 2 H-phenyl, lH-pyrazol-1-yl, l-Me-lH-pyrazol-4-yl, l-Me-lH-pyrazol-5-yl, l-Et-lH-pyrazol-5-yl, oxazol-2-yl, 3,5-diMe-isoxazol-4-yl, 2-thiazolyl, lH-imidazol-1-yl, 3,5
  • R 9 is H, F, Cl, Br, I, or C 1-4 alkyl.
  • R 9 is H, F, or Cl.
  • R 9 is H or F.
  • R 9 is H.
  • R 10 is H, F, Cl, Br, I, or C 1-4 alkyl.
  • R 10 is H, F, or Cl.
  • R 10 is H or F.
  • R 10 is H.
  • R 1 1 is H, F, Cl, Br, I, or C 1-4 alkyl.
  • R 11 is H, F, or Cl.
  • R 11 is H or F.
  • R 1 1 is H.
  • the present invention provides a composition comprising at least one of the compounds of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.
  • the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.
  • the present invention provides a process for making a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the present invention provides an intermediate for making a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the present invention provides a pharmaceutical composition further comprising additional therapeutic agent(s).
  • the present invention provides a pharmaceutical composition, wherein the additional therapeutic agent(s) are an anti-platelet agent or a combination thereof.
  • the anti-platelet agent(s) are clopidogrel and/or aspirin, or a combination thereof.
  • the present invention provides a method for the treatment or prophylaxis of a thromboembolic disorder comprising: administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of at least one of the compounds of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.
  • the present invention provides a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, for use in therapy for the treatment or prophylaxis of a thromboembolic disorder.
  • the present invention also provides the use of a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, for the manufacture of a medicament for the treatment or prophylaxis of a thromboembolic disorder.
  • the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, arterial cerebrovascular thromboembolic disorders, and venous cerebrovascular thromboembolic disorders.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the present invention provides a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, for use in therapy.
  • the present invention provides a method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and the second therapeutic agent is at least one agent selected from a second factor Xa inhibitor, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, and a fibrinolytic agent.
  • the present invention provides a first and second therapeutic agent for use in treating treating a thromboembolic disorder, wherein the first therapeutic agent is a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and the second therapeutic agent is at least one agent selected from a second factor Vila inhibitor, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, and a fibrinolytic agent.
  • the first therapeutic agent is a compound of the present invention or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof
  • the second therapeutic agent is at least one agent selected from a second factor Vila inhibitor, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, and a fibrinolytic agent.
  • the second therapeutic agent is at least one agent selected from warfarin, unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, hirudin, argatroban, aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, melagatran, disulfatohirudin, tissue plasminogen activator, modified tissue plasminogen activator, anistreplase, urokinase, and streptokinase.
  • the second therapeutic agent is at least one anti-platelet agent.
  • the anti-platelet agent(s) are clopidogrel and/or aspirin, or a combination thereof.
  • the present invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy.
  • the present invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in treatment or prophylaxis of a thromboembolic disorder.
  • Compounds of this invention may have one or more asymmetric centers.
  • Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis using optically active starting materials or optically active catalysts.
  • Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
  • the molecular weight of compounds of the present invention is preferably less than about 800 grams per mole.
  • alkyl or “alkylene” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • “Ci-Io alkyl” (or alkylene), is intended to include Ci, C2, C3, C4, C5, Ce, C 7 , Cs, C9, and Cio alkyl groups.
  • Ci -6 alkyl denotes alkyl having 1 to 6 carbon atoms.
  • Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced by another chemical group.
  • alkyl examples include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec -butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n- hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl.
  • Me methyl
  • Et ethyl
  • propyl e.g., n-propyl and i-propyl
  • butyl e.g., n-butyl, i-butyl, sec -butyl, and t-butyl
  • pentyl e.g., n-p
  • alkenyl or “alkenylene” is intended to include hydrocarbon chains of either a straight or branched configuration having the specified number of carbon atoms and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain.
  • C2-6 alkenyl (or alkenylene), is intended to include C2, C3, C4, C5, and C ⁇ alkenyl groups.
  • alkenyl examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3, pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3 -pentenyl, and the like.
  • Alkynyl or “alkynylene” is intended to include hydrocarbon chains of either a straight or branched configuration having one or more carbon-carbon triple bonds which may occur in any stable point along the chain.
  • C2-6 alkynyl (or alkynylene), is intended to include C2, C3, C4, C5, and C ⁇ alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
  • Alkoxy or “alkyloxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • Ci_6 alkoxy (or alkyloxy), is intended to include Ci, C2, C3, C4, C5, and C(, alkoxy groups.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy.
  • alkylthio or “thioalkoxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S-, and ethyl-S-.
  • Halo or "halogen” as used herein refers to fluoro, chloro, bromo, and iodo.
  • Haloalkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen.
  • haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.
  • haloalkyl also include "fluoroalkyl” which is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more fluorine atoms.
  • Haloalkoxy or "haloalkyloxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • Ci_6 haloalkoxy is intended to include Ci, C2, C3, C4, C5, and C6 haloalkoxy groups.
  • haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluorothoxy.
  • haloalkylthio or “thiohaloalkoxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example trifluoromethyl-S-, and pentafluoroethyl-S-.
  • cycloalkyl refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems.
  • C3 -7 cycloalkyl is intended to include C3, C4, C5, C ⁇ , and C 7 cycloalkyl groups.
  • Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl.
  • Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl".
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
  • bridged rings are also included in the definition of carbocycle (e.g., [2.2.2]bicyclooctane).
  • carbocycles e.g., [2.2.2]bicyclooctane
  • Preferred carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, and indanyl.
  • carbocycle When the term “carbocycle” is used, it is intended to include “aryl”.
  • a bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms.
  • Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring.
  • bicyclic carbocycle or "bicyclic carbocyclic group” is intended to mean a stable 9 or 10-membered carbocyclic ring system that contains two fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to a second ring; and the second ring is a 5 or 6 membered carbon ring which is saturated, partially unsaturated, or unsaturated.
  • the bicyclic carbocyclic group may be attached to its pendant group at any carbon atom which results in a stable structure.
  • bicyclic carbocyclic group described herein may be substituted on any carbon if the resulting compound is stable.
  • Examples of a bicyclic carbocyclic group are, but not limited to, naphthyl, 1 ,2-dihydronaphthyl, 1,2,3,4- tetrahydronaphthyl, and indanyl.
  • Aryl refer to monocyclic or poly cyclic aromatic hydrocarbons, including, for example, phenyl, naphthyl, and phenanthranyl. Aryl moieties are well known and described, for example, in Hawley's Condensed Chemical Dictionary (13 ed.), RJ. Lewis, ed., J.
  • C6-io aryl refers to phenyl or naphthyl. Unless otherwise specified, "aryl", “C6-io aryl” or “aromatic residue” may be unsubstituted or substituted with 1 to 3 groups selected from H, OH, OCH 3 , Cl, F, Br, I, CN, NO 2 , NH 2 , N(CH 3 )H, N(CH 3 ) 2 ,
  • heterocycle or “heterocyclic group” is intended to mean a stable 3-, 4-, 5-, 6-, or 7- membered monocyclic or polycyclic or 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated, partially unsaturated or fully unsaturated, and that consists of carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; and including any polycyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized to -NO-, -SO-, or -SO 2 -.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
  • heterocycle it is intended to include heteroaryl.
  • heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3- ⁇ ]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl
  • fused ring and spiro compounds containing, for example, the above heterocycles are fused ring and spiro compounds containing, for example, the above heterocycles.
  • 5- to 10-membered heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, lH-indazolyl, benzofuranyl, benzothiofuranyl, benztetra
  • Examples of 5- to 6-membered heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.
  • bicyclic heterocycle or "bicyclic heterocyclic group” is intended to mean a stable 9 or 10-membered heterocyclic ring system which contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S. Of the two fused rings, one ring is a 5 or 6-membered monocyclic aromatic ring comprising a 5 membered heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second ring.
  • the second ring is a 5 or 6 membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5 membered heterocycle, a 6 membered heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a carbocycle).
  • the bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
  • Examples of a bicyclic heterocyclic group are, but not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, lH-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydro-quinolinyl, 2,3-dihydro-benzofuranyl, chromanyl, 1,2,3,4-tetrahydro-quinoxalinyl, and 1,2,3,4- tetrahydro-quinazolinyl.
  • aromatic heterocyclic group or "heteroaryl” is intended to mean stable monocyclic and polycyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
  • Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzod
  • Bridged rings are also included in the definition of heterocycle.
  • a bridged ring occurs when one or more atoms (i.e., C, O, N, or S) link two non- adjacent carbon or nitrogen atoms.
  • Examples of bridge rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
  • the term "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.
  • a dotted ring is used within a ring structure, this indicates that the ring structure may be saturated, partially saturated or unsaturated.
  • nitrogen atoms e.g., amines
  • these may be converted to N-oxides by treatment with an oxidizing agent (e.g., mCPBA and/or hydrogen peroxides) to afford other compounds of this invention.
  • an oxidizing agent e.g., mCPBA and/or hydrogen peroxides
  • shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N- >O) derivative.
  • these may be replaced by silicon atoms, provided they do not form Si-N or Si-O bond.
  • any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
  • a group is shown to be substituted with 0-3 R f , then said group may optionally be substituted with up to three R f groups and R f at each occurrence is selected independently from the definition of R f .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, and/or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18 th Edition, Mack Publishing Company, Easton, PA, 1990, the disclosure of which is hereby incorporated by reference.
  • compounds of formula I may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i.e., a compound of formula I) is a prodrug within the scope and spirit of the invention.
  • a prodrug within the scope and spirit of the invention.
  • Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985), and Methods in Enzymology, Vol. 42, at pp. 309-396, edited by K. Widder, et. al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs," by H.
  • Bundgaard at pp. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, Vol. 8, p. 1-38 (1992); d) H. Bundgaard, et ah, Journal of Pharmaceutical Sciences, Vol. 77, p. 285 (1988); and e) N. Kakeya, et. al, Chem Phar Bull, Vol. 32, p. 692 (1984).
  • compositions containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula I compounds per se.
  • prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester per se is active, or in those instances where hydrolysis occurs in the blood.
  • physiologically hydrolyzable esters of compounds of formula I include C 1 ⁇ alkyl , C 1 ⁇ alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, Ci_6 alkanoyloxy-Ci ⁇ alkyl (e.g. acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl),
  • esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art. [0088] Preparation of prodrugs is well known in the art and described in, for example, Medicinal Chemistry: Principles and Practice, ed. F. D. King, The Royal Society of Chemistry, Cambridge, UK, 1994.
  • Isotopically labeled compounds of the present invention i.e., wherein one or more of the atoms described are replaced by an isotope of that atom (e.g., 12 C replaced by 13 C or by 14 C; and isotopes of hydrogen include tritium and deuterium), are also provided herein.
  • Such compounds have a variety of potential uses, e.g., as standards and reagents in determining the ability of a potential pharmaceutical compound to bind to target proteins or receptors, or for imaging compounds of this invention bound to biological receptors in vivo or in vitro.
  • Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 98%, preferably 99%, compound of the present invention ("substantially pure"), which is then used or formulated as described herein. Such “substantially pure” compounds are also contemplated herein as part of the present invention.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. It is preferred that compounds of the present invention do not contain a N-halo, S(O ⁇ H, or S(O)H group.
  • solvate means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • solvent encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates and the like. Methods of solvation are generally known in the art.
  • AD-mix-beta contains potassium osmate, potassium ferricyanide, potassium carbonate and hydroquinidine 1,4 -phthalazinediyl diether, AIBN is azo-bis-isobutyrlnitrile,
  • 9-BBN is 9-borabicyclo[3.3.1]nonane
  • BINAP is 2,2'-bis(diphenylphosphino)-l,r-binaphthalene
  • Bn is benzyl
  • Boc is tert-butyl oxycarbonyl
  • BOM is benzyloxymethyl
  • BOP is benzotriazol-l-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
  • Bu is butyl, iBu or /-Bu is isobutyl, /-Bu is ZerZ-butyl,
  • DCE 1,2-dichloroethane
  • DCM or CH2CI2 is dichloromethane
  • DIBAH is diisobutylaluminum hydride
  • DIC is 1,3-diisopropylcarbodiimide
  • DIEA diethylpropyl amine
  • DMAP is dimethylaminopyridine
  • DME is dimethyl ether
  • DMF is dimethylformamide
  • DMPU is l,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone
  • DMSO dimethyl sulfoxide
  • DPPA diphenylphosphoryl azide
  • EDCI is l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • Et is ethyl
  • EtOH is ethanol
  • HEPES is 4-(2-hydroxyethyl)piperaxine-l-ethanesulfonic acid
  • HOAt or HOAT is 1 -hydroxy-7-azabenzotriazole
  • HOBt is 1-hydroxybenzotriaole hydrate
  • LAH is lithium aluminum hydride
  • LDA is lithium diisopropylamide
  • LiHMDS is bis(trimethylsilyl)amide
  • mCPBA or MCPBA is meto-chloroperbenzoic acid
  • Me is methyl
  • MeOH is methanol
  • MsCl is methanesulfonyl chloride
  • NaHMDS sodium hexamethyldisilazane
  • NaOAc sodium actetate
  • NBS N-bromosuccinimide
  • OAc acetate
  • Pd2(dba) 3 is tris(dibenzylideneacetone)dipalladium(0)
  • Pd(PPh 3 ) 4 is tetraks (triphenylphosphine) palladium
  • Ph is phenyl
  • PMDTA is N,N,N',N',N"-pentametliyldietliylenetriamine
  • Pr is propyl
  • PyBOP is benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
  • iPr or /-Pr is isopropyl
  • i-PrOH or IPA is isopropanol
  • TBAF is tetrabutylammoniumfluoride
  • TBAI is tetrabutylammonium iodide
  • TBS is tert-butyldimethylsilyl
  • TBDMS-Cl is tert-butyldiphenylchlorosilane
  • TBDPS-Cl is tert-butyldimethylchlorosilane
  • TBSCl is tert-butyldimethylsilyl chloride
  • TEA is triethylamine
  • TEMPO is 2,2,6,6-tetramethylpiperidine-l-oxyl
  • TFA is trifluoroacetic acid
  • TFAA is trifluoroacetic anhydride
  • THF is tetrahydrofuran
  • TrCl is trityl chloride
  • TRIS is tris(hydroxymethyl)aminomethane
  • Tr is trityl
  • Xantphos is 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.
  • the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the reactions are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
  • This reaction is typically conducted in a solvent such as, but not limited to, toluene, dichloromethane, 1,2-dichloroethane, methanol, ethanol, dimethylformamide, or acetonitrile, or appropriate mixtures thereof. In some cases, mixtures of acetonitrile and dimethylformamide are preferred. Fluorinated alcohols such as hexafluoroisopropanol are useful additives that may improve the rate and or yield of the reaction. If necessary, the reaction is heated conventionally or in a microwave reactor to achieve a practical reaction rate. [0097] The preparation of amines 1 is described in the experimental procedures for Intermediates 1-7 and 12.
  • the protecting group PG in 2 may be, for instance, a carbamate such as Boc or Cbz, or the entire PGNR 5 CR 6 R 7 group may be a nitrile, which may be deprotected by catalytic hydrogenation to an unsubstituted benzylamine.
  • the protecting group is removed under appropriate conditions from arylglycines 3 to provide amino acids 4.
  • Amino acids 4 can be cyclized to macrocycles 5 under conditions suitable for forming an amide bond between the acid and the amine.
  • Coupling reagents and conditions can be found in Bodanszky, "Principles of Peptide Synthesis, Second Edition” Springer Verlag Ed, Berlin (1993) and in a recent review (Montalbetti, C. A. G. N., Falque, V. Tetrahedron 2005, 61, 10819-11046).
  • Coupling reagents include, but not limited to, CDI, DIC, and EDCI.
  • an intermediate activated ester can be prepared by adding one equivalent of 1-hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole.
  • Other coupling reagents include, but not limited to, BOP or HATU, which are usually reacted in the presence of a tertiary base such as DIEA or TEA.
  • BOP is a preferred reagent for preparation of compounds of Formula (I).
  • Addition of catalytic or stoichiometric DMAP may improve the reaction rate or yield.
  • the reaction may be conducted in solvents such as, but not limited to, DCE, DCM, DMF, or mixtures thereof.
  • the cyanohydrins are reacted with hydrogen chloride in methanol, and the intermediate imidates are hydrolyzed to afford methyl esters 8.
  • the hydroxyl group in 8 is converted to a leaving group (LG) such as halogen or sulfonate. Chloride and triflate are preferred LGs for this reaction.
  • Nucleophiles W-ZH are reacted with 9 in a solvent such as DCM or DMF and in presence of a base such as 2,6-lutidine, TEA, or DIEA to afford 10.
  • the protecting group in 10 is removed and 11, containing nucleophilic groups YH is reacted with phenyl carbamates 12, or their synthetic equivalent isocyanate or carbamoyl halide to give 13.
  • the methyl ester in 13 is hydrolyzed and the nitrogen protecting group (PG) is removed to give amino acids 14. Subsequent cyclization as described in Scheme 1 affords macrocycles 15.
  • aldehydes 6 can be condensed with trimethylsilylcyanide in presence of ammonia to give aminonitriles 16.
  • Amino esters 17 may be coupled with aryl or heteroaryl halides or sulfonates W-LG by methods known in the art.
  • amino esters 17 may be coupled to W-LG in the presence of a palladium catalyst, an appropriate ligand, for example, BINAP, using a base such as cesium carbonate to provide esters 18.
  • Esters 18 are a subset of esters 10 in Scheme 2, and can be converted to compounds of Formula (I) using the subsequent methods described in Scheme 2.
  • Nitro fluoride 36 may be treated with thiols to afford sulfides 37.
  • Compounds 37 can be oxidized with mCPBA to sulfones 38.
  • iron/acetic acid reduction of 37 to aniline 40, followed by borane reduction gives benzylamine 41.
  • H can be achieved as shown in Scheme 9.
  • Nitro fluoride 43 may be treated with thiols to afford sulfides.
  • the acid can then be converted to methyl amides 44 through the acid chloride.
  • Subsequent reductions with iron/acetic acid and borane give benzyl amines 46.
  • Compounds 48 (prepared according to the Schemes 1-4) are deprotected (PG' protecting group) to afford acids 49, which in turn are coupled with amines 50 to afford amides 51.
  • PG protecting group
  • nitro functional group reduction reducing conditions, such as H 2 , Pd- C or Fe, AcOH
  • the compounds of the instant invention herein described may have asymmetric centers.
  • the chiral carbon atom in Formula (I) (indicated with an asterisk below) exists either in the S or R configuration.
  • the stereoisomeric configurations of each compound of Formula (I) are considered part of the invention.
  • the present invention provides for the R configuration at the indicated chiral carbon for all embodiments of Formula (I), or tautomers, pharmaceutically acceptable salts, solvates, or prodrug forms thereof.
  • Products were analyzed by reverse phase analytical HPLC carried out on a Shimadzu Analytical HPLC system running DiscoveryVP software using Column 1 (SunFire C18; 3.5 urn; 4.6 x 150 mm) and Column 2 ( XBridge Phenyl 3.5 wm; 4.6 x 150 mm) eluted at 1 mL/min with a 10 min gradient from 100% A to 100% B and holding 100% B for 5 min while monitoring at 220 nM and 254 nM. Purities are reported at 254 nM.
  • Method A Solvent A: 10% methanol, 90% water, 0.05% TFA; Sovent B: 10% water, 90% methanol, 0.05% TFA, UV 254 nm) and Method B: Solvent A: 5% acetonitrile, 95% water , 0.05% NH 4 HCO 3 . Solvent B: 95% acetonitrile, 5% water, 0.05% NH 4 HCO 3 . Purification of intermediates and final products was carried out via either normal or reverse phase chromatography. Normal phase chromatography was carried out on an ISCO CombiFlashTM System using prepacked Si ⁇ 2 cartridges eluted with gradients of hexanes and ethyl acetate.
  • Reverse phase preparative HPLC was carried out using a Shimadzu Preparative HPLC system running DiscoveryVP software using Method A: Waters Sunfire 5 ⁇ m Cl 8 30x100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm), Method B: Phenomenex AXIA Luna 5 ⁇ m C18 30 x 75 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9% acetonitrile, 0.1% TFA, UV 220 nm), Method C: Phenomenex Luna 5 ⁇ m C18 30 x 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% acetonit
  • blood coagulation is essential to the regulation of an organism's hemostasis, it is also involved in many pathological conditions.
  • a blood clot, or thrombus may form and obstruct circulation locally, causing ischemia and organ damage.
  • embolism the clot may dislodge and subsequently become trapped in a distal vessel, where it again causes ischemia and organ damage.
  • thromboembolic disorders Diseases arising from pathological thrombus formation are collectively referred to as thromboembolic disorders and include acute coronary syndrome, unstable angina, myocardial infarction, thrombosis in the cavity of the heart, ischemic stroke, deep vein thrombosis, peripheral occlusive arterial disease, transient ischemic attack, and pulmonary embolism.
  • thrombosis occurs on artificial surfaces in contact with blood, including catheters, stents, and artificial heart valves.
  • thrombosis Some conditions contribute to the risk of developing thrombosis. For example, alterations of the vessel wall, changes in the flow of blood, and alterations in the composition of the vascular compartment. These risk factors are collectively known as Virchow's triad. (Hemostasis and Thrombosis, Basic Principles and Clinical practice, page 853, 5 th Edition, 2006, edited by Colman, R. W. et al. Published by Lippincott Williams & Wilkins) [00110] Antithrombotic agents are frequently given to patients at risk of developing thromboembolic disease because of the presence of one or more predisposing risk factors from Virchow's triad to prevent formation of an occlusive thrombus (primary prevention).
  • an antithrombotic agent is frequently administered prior to a surgical procedure.
  • the antithrombotic agent counterbalances the prothrombotic stimulus exerted by vascular flow alterations (stasis), potential surgical vessel wall injury, as well as changes in the composition of the blood due to the acute phase response related to surgery.
  • Another example of the use of an antithrombotic agent for primary prevention is dosing with aspirin, a platelet activation inhibitor, in patients at risk for developing thrombotic cardiovascular disease.
  • Well recognized risk factors in this setting include age, male gender, hypertension, diabetes mellitus, lipid alterations, and obesity.
  • Antithrombotic agents are also indicated for secondary prevention, following an initial thrombotic episode.
  • patients with mutations in factor V also known as factor V Leiden
  • additional risk factors e.g., pregnancy
  • anticoagulants are dosed with anticoagulants to prevent the reoccurrence of venous thrombosis.
  • Another example entails secondary prevention of cardiovascular events in patients with a history of acute myocardial infarction or acute coronary syndrome.
  • a combination of aspirin and clopidogrel may be used to prevent a second thrombotic event.
  • Antithrombotic agents are also given to treat the disease state (i.e., by arresting its development) after it has already started.
  • patients presenting with deep vein thrombosis are treated with anticoagulants (i.e. heparin, warfarin, or LMWH) to prevent further growth of the venous occlusion.
  • anticoagulants i.e. heparin, warfarin, or LMWH
  • these agents also cause a regression of the disease state because the balance between prothrombotic factors and anticoagulant/profibrinolytic pathways is changed in favor of the latter.
  • antithrombotic agents are used widely for primary and secondary prevention (i.e., prophylaxis or risk reduction) of thromboembolic disorders, as well as treatment of an already existing thrombotic process.
  • Drugs that inhibit blood coagulation, or anticoagulants are "pivotal agents for prevention and treatment of thromboembolic disorders" (Hirsh, J. et al. Blood 2005, 105, 453-463).
  • a biological factor Vila inhibitor XKl comprising a hybrid of Factor X light chain and tissue factor pathway inhibitor first kunitz domain, prevents thrombus formation in a rat model of arterial thrombosis, with no change in bleeding time or total blood loss (Szalony, J. A. et al. J. Thrombosis and Thrombolysis 2002, 14, 113-121).
  • small molecule active site directed factor Vila inhibitors have demonstrated antithrombotic efficacy in animal models of arterial thrombosis (Suleymanov, O., et al. J Pharmacology and Experimental Therapeutics 2003, 306, 1115-1121; Olivero, A. G. et al. J.
  • rNAPc2 biological factor Vila inhibitor recombinant nematode anticoagulant protein c2
  • aPTT activated partial thromboplastin time
  • PT prothrombin time
  • the term "patient” encompasses all mammalian species.
  • "treating” or “treatment” cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) inhibiting the disease-state, i.e., arresting its development; and/or (b) relieving the disease-state, i.e., causing regression of the disease state.
  • prophylaxis or 'prevention' cover the preventive treatment of a subclinical disease-state in a mammal, particularly in a human, aimed at reducing the probability of the occurance of a clinical disease-state.
  • Patients are selected for preventative therapy based on factors that are known to increase risk of suffering a clinical disease state compared to the general population.
  • "Prophylaxis” therapies can be divided into (a) primary prevention and (b) secondary prevention.
  • Primary prevention is defined as treatment in a subject that has not yet presented with a clinical disease state, whereas secondary prevention is defined as preventing a second occurance of the same or similar clinical disease state.
  • risk reduction covers therapies that lower the incidence of development of a clinical disease state. As such, primary and secondary prevention therapies are examples of risk reduction.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination with other active ingredients to inhibit factor Vila or to prevent or treat the disorders listed herein. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the preventive or therapeutic effect, whether administered in combination, serially or simultaneously.
  • thrombosis refers to formation or presence of a thrombus (pi.
  • thrombi clotting within a blood vessel that may cause ischemia or infarction of tissues supplied by the vessel.
  • emblism refers to sudden blocking of an artery by a clot or foreign material that has been brought to its site of lodgment by the blood current.
  • thromboembolism refers to obstruction of a blood vessel with thrombotic material carried by the blood stream from the site of origin to plug another vessel.
  • thromboembolic disorders entails both "thrombotic” and “embolic” disorders (defined vide supra).
  • thromboembolic disorders includes arterial or venous cardiovascular or cerebovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart or in the peripheral circulation.
  • thromboembolic disorders also includes specific disorders selected from, but not limited to, unstable angina or other acute coronary syndromes, atrial fibrillation, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolisms, pulmonary embolisms, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the medical implants or devices include, but are not limited to: prosthetic valves, artificial valves, indwelling catheters, stents, blood oxygenators, shunts, vascular access ports, and vessel grafts.
  • the procedures include, but are not limited to: cardiopulmonary bypass, percutaneous coronary intervention, and hemodialysis.
  • thromboembolic disorders includes acute coronary syndrome, stroke, deep vein thrombosis, and pulmonary embolism.
  • the present invention provides a method for the treatment of a thromboembolic disorder, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis,
  • the present invention provides a method for the treatment of a thromboembolic disorder, wherein the thromboembolic disorder is selected from acute coronary syndrome, stroke, venous thrombosis, atrial fibrillation, and thrombosis resulting from medical implants and devices.
  • the present invention provides a method for the primary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease,
  • the present invention provides a method for the primary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from acute coronary syndrome, stroke, venous thrombosis, and thrombosis resulting from medical implants and devices.
  • the present invention provides a method for the secondary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, recurrent myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.
  • the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, recurrent myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombo
  • the present invention provides a method for the secondary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from acute coronary syndrome, stroke, atrial fibrillation and venous thrombosis.
  • stroke refers to embolic stroke or atherothrombotic stroke arising from occlusive thrombosis in the carotid communis, carotid interna, or intracerebral arteries.
  • thrombosis includes vessel occlusion (e.g. after a bypass) and reocclusion (e.g., during or after percutaneous transluminal coronary angioplasty).
  • the thromboembolic disorders may result from conditions including but not limited to atherosclerosis, surgery or surgical complications, prolonged immobilization, atrial fibrillation, congenital thrombophilia, cancer, diabetes, effects of medications or hormones, and complications of pregnancy.
  • Thromboembolic disorders are frequently associated with patients with atherosclerosis.
  • Risk factors for atherosclerosis include but are not limited to male gender, age, hypertension, lipid disorders, and diabetes mellitus. Risk factors for atherosclerosis are at the same time risk factors for complications of atherosclerosis, i.e., thromboembolic disorders.
  • thromboembolic disorders Similarly, arterial fibrillation is frequently associated with thromboembolic disorders. Risk factors for arterial fibrillation and subsequent thromboembolic disorders include cardiovascular disease, rheumatic heart disease, nonrheumatic mitral valve disease, hypertensive cardiovascular disease, chronic lung disease, and a variety of miscellaneous cardiac abnormalities as well as thyrotoxicosis.
  • Diabetes mellitus is frequently associated with atherosclerosis and thromboembolic disorders.
  • Risk factors for the more common type 2 include but are not limited to are family history, obesity, physical inactivity, race / ethnicity, previously impaired fasting glucose or glucose tolerance test, history of gestational diabetes mellitus or delivery of a 'big baby', hypertension, low HDL cholesterol, and polycystic ovary syndrome.
  • Risk factor for congenital thrombophilia include gain of function mutations in coagulation factors or loss of function mutations in the anticoagulant- or fibrinolytic pathways.
  • Thrombosis has been associated with a variety of tumor types, e.g., pancreatic cancer, breast cancer, brain tumors, lung cancer, ovarian cancer, prostate cancer, gastrointestinal malignancies, and Hodgkins or non-Hodgkins lymphoma.
  • tumor types e.g., pancreatic cancer, breast cancer, brain tumors, lung cancer, ovarian cancer, prostate cancer, gastrointestinal malignancies, and Hodgkins or non-Hodgkins lymphoma.
  • Recent studies suggest that the frequency of cancer in patients with thrombosis reflects the frequency of a particular cancer type in the general population. (Levitan, N. et al Medicine (Baltimore) 1999, 78(5):285-291; Levine M. et al. N Engl J Med 1996, 334(11):677-681; Blom, J. W.
  • VTE venous thromboembolism
  • the effectiveness of compounds of the present invention as inhibitors of the coagulation factors Vila, IXa, Xa, XIa, XIIa or thrombin can be determined using a relevant purified serine protease, respectively, and an appropriate synthetic substrate. The rate of hydrolysis of the chromogenic substrate by the relevant serine protease was measured both in the absence and presence of compounds of the present invention.
  • Factor Vila determinations were made in 0.005 M calcium chloride, 0.15 M sodium chloride, 0.05 M HEPES buffer containing 0.1% PEG 8000 at a pH of 7.5. Determinations were made using purified human Factor Vila (Haematologic Technologies) or recombinant human Factor Vila (Novo Nordisk) at a final assay concentration of 1-5 nM, recombinant soluble tissue factor at a concentration of 10-40 nM and the synthetic substrate H-D-Ile-Pro-Arg-pNA (S-2288; Chromogenix or BMPM-2; AnaSpec) at a concentration of 0.001-0.0075 M.
  • Refludan was added to inhibit small amounts of thrombin in the commercial preparations of human Factor IXa. Determinations were made using purified human Factor IXa (Haematologic Technologies) at a final assay concentration of 20-100 nM and the synthetic substrate PCIXA2100-B (CenterChem) or Pefafluor IXa 3688 (H-D-Leu-Phe-Gly-Arg-AMC; CenterChem) at a concentration of 0.0004-0.0005 M.
  • Factor Xa determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.4 containing 0.2 M sodium chloride and 0.5% PEG 8000. Determinations were made using purified human Factor Xa (Haematologic Technologies) at a final assay concentration of 150-1000 pM and the synthetic substrate S-2222 (Bz-Ile-Glu(gamma-OMe, 50%)-Gly-Arg-pNA; Chromogenix) at a concentration of 0.0002-0.00035 M. [00136] Factor XIa determinations were made in 50 mM HEPES buffer at pH
  • K m The Michaelis constant, K m , for substrate hydrolysis by each protease was determined at 25 0 C using the method of Lineweaver and Burk. Values of Kj were determined by allowing the protease to react with the substrate in the presence of the inhibitor. Reactions were allowed to go for periods of 20-180 minutes (depending on the protease) and the velocities (rate of absorbance change vs time) were measured. The following relationship was used to calculate Kj values:
  • Ki IC5o/(l + S/Km) for a competitive inhibitor where: V 0 is the velocity of the control in the absence of inhibitor; v s is the velocity in the presence of inhibitor;
  • I is the concentration of inhibitor
  • A is the minimum activity remaining (usually locked at zero);
  • n is the Hill coefficient, a measure of the number and cooperativity of potential inhibitor binding sites
  • IC50 is the concentration of inhibitor that produces 50% inhibition under the assay conditions
  • Ki is the dissociation constant of the enzyme: inhibitor complex; S is the concentration of substrate; and
  • K m is the Michaelis constant for the substrate.
  • Compounds with selectivity ratios >20 are considered selective.
  • Compounds with selectivity ratios >100 are preferred, and compounds with selectivity ratios > 500 are more preferred.
  • the effectiveness of compounds of the present invention as inhibitors of coagulation can be determined using a standard or modified clotting assay.
  • An increase in the plasma clotting time in the presence of inhibitor is indicative of anticoagulation.
  • Relative clotting time is the clotting time in the presence of an inhibitor divided by the clotting time in the absence of an inhibitor.
  • the results of this assay may be expressed as IC1.5x or IC2x, the inhibitor concentration required to increase the clotting time by 50 or 100 percent, respectively.
  • the ICl.5x or IC2x is found by linear interpolation from relative clotting time versus inhibitor concentration plots using inhibitor concentration that spans the ICl.5x or IC2x.
  • Clotting times are determined using citrated normal human plasma as well as plasma obtained from a number of laboratory animal species (e.g., rat, or rabbit). A compound is diluted into plasma beginning with a 10 mM DMSO stock solution. The final concentration of DMSO is less than 2%. Plasma clotting assays are performed in an automated coagulation analyzer (Sysmex, Dade-Behring, Illinois). Similarly, clotting times can be determined from laboratory animal species or humans dosed with compounds of the invention. [0008] Activated Partial Thromboplastin Time (aPTT) is determined using Alexin (Trinity Biotech, Ireland) following the directions in the package insert.
  • Alexin Trinity Biotech, Ireland
  • Plasma 0.05 mL is warmed to 37°C for 1 minute. Alexin (0.05 mL) is added to the plasma and incubated for an additional 2 to 5 minutes. Calcium chloride (25 mM, 0.05 mL) is added to the reaction to initiate coagulation. The clotting time is the time in seconds from the moment calcium chloride is added until a clot is detected.
  • Prothrombin Time PT is determined using thromboplastin
  • Plasma 0.05 mL
  • Thromboplastin 0.1 mL
  • the clotting time is the time in seconds from the moment thromboplastin is added until a clot is detected.
  • Ther 2000, 295, 212-218 can be used in this study.
  • Male New Zealand White rabbits are anesthetized with ketamine (50 mg/kg + 50 mg/kg/h IM) and xylazine (10 mg/kg + 10 mg/kg/h IM). These anesthetics are supplemented as needed.
  • An electromagnetic flow probe is placed on a segment of an isolated carotid artery to monitor blood flow. Test agents or vehicle will be given (Lv., Lp., s.c, or orally) prior to or after the initiation of thrombosis.
  • Drug treatment prior to initiation of thrombosis is used to model the ability of test agents to prevent and reduce the risk of thrombus formation, whereas dosing after initiation is used to model the ability to treat existing thrombotic disease.
  • Thrombus formation is induced by electrical stimulation of the carotid artery for 3 min at 4 mA using an external stainless-steel bipolar electrode. Carotid blood flow is measured continuously over a 90-min period to monitor thrombus-induced occlusion. Total carotid blood flow over 90 min is calculated by the trapezoidal rule.
  • Average carotid flow over 90 min is then determined by converting total carotid blood flow over 90 min to percent of total control carotid blood flow, which would result if control blood flow had been maintained continuously for 90 min.
  • the ED50 (dose that increased average carotid blood flow over 90 min to 50% of the control) of compounds are estimated by a nonlinear least square regression program using the Hill sigmoid E max equation (DeltaGraph; SPSS Inc., Chicago, IL).
  • the AV shunt also contains an 8-cm-long 2-0 silk thread (Ethicon, Somerville, NJ). Blood flows from the femoral artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread induces the formation of a significant thrombus. Forty minutes later, the shunt is disconnected and the silk thread covered with thrombus is weighed.
  • Test agents or vehicle will be given (Lv., Lp., s.c, or orally) prior to the opening of the AV shunt.
  • the percentage inhibition of thrombus formation is determined for each treatment group.
  • the ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by a nonlinear least square regression program using the Hill sigmoid E max equation (DeltaGraph; SPSS Inc., Chicago, IL).
  • the compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • pharmaceutical composition means a composition comprising a compound of the invention in combination with at least one additional pharmaceutical acceptable carrier.
  • a “pharmaceutically acceptable carrier” refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals, including, i.e., adjuvant, excipient or vehicle, such as diluents, preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art.
  • Pharmaceutically acceptable carriers include both aqueous and nonaqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Remington 's Pharmaceutical Sciences, 18 th Edition, 1990.
  • the dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.
  • a physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.
  • the daily oral dosage of each active ingredient when used for the indicated effects, will range between about 0.001 to about 1000 mg/kg of body weight, preferably between about 0.01 to about 100 mg/kg of body weight per day, and most preferably between about 0.1 to about 20 mg/kg/day.
  • the most preferred doses will range from about 0.001 to about 10 mg/kg/minute during a constant rate infusion.
  • Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
  • Compounds of this invention can also be administered by parenteral administration (e.g., intra-venous, intra-arterial, intra-musculary, or sub-cutaneously.
  • parenteral administration e.g., intra-venous, intra-arterial, intra-musculary, or sub-cutaneously.
  • the dose can be given continuously or intermittend.
  • formulation can be developed for intramusculary and subcutaneous delivery that ensure a gradual release of the active pharmaceutical ingredient.
  • Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, e.g., oral tablets, capsules, elixirs, and syrups, and consistent with conventional pharmaceutical practices.
  • suitable pharmaceutical diluents, excipients, or carriers suitably selected with respect to the intended form of administration, e.g., oral tablets, capsules, elixirs, and syrups, and consistent with conventional pharmaceutical practices.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
  • Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
  • Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 1000 milligrams of active ingredient per dosage unit.
  • Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl-or propyl-paraben, and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's
  • a daily dosage may be about 0.1 to about 100 milligrams of the compound of the present invention and about 0.1 to about 100 milligrams per kilogram of patient body weight.
  • the compounds of this invention generally may be present in an amount of about 5 to about 100 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to about 50 milligrams per dosage unit.
  • a daily dosage may be about 0.01 to about 25 milligrams of the compound of the present invention and about 50 to about 150 milligrams of the anti-platelet agent, preferably about 0.1 to about 1 milligrams of the compound of the present invention and about 1 to about 3 milligrams of antiplatelet agents, per kilogram of patient body weight.
  • a daily dosage may be about 0.1 to about 1 milligrams of the compound of the present invention, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 50-80% when administered with a compound of the present invention.
  • one active ingredient may be enteric coated.
  • enteric coating one of the active ingredients it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines.
  • One of the active ingredients may also be coated with a material that affects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.
  • the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine.
  • Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components.
  • HPMC hydroxypropyl methylcellulose
  • the polymer coating serves to form an additional barrier to interaction with the other component.
  • the present invention provides a pharmaceutical composition further comprising additional therapeutic agent(s) selected from potassium channel openers, potassium channel blockers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, antiatherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phospodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents,
  • the present invention provides a pharmaceutical composition further comprising additional therapeutic agent(s) selected from an anti-arrhythmic agent, an anti-hypertensive agent, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, a fibrinolytic agent, a calcium channel blocker, a potassium channel blocker, a cholesterol/lipid lowering agent, or a combination thereof.
  • additional therapeutic agent(s) selected from an anti-arrhythmic agent, an anti-hypertensive agent, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, a fibrinolytic agent, a calcium channel blocker, a potassium channel blocker, a cholesterol/lipid lowering agent, or a combination thereof.
  • the present invention provides a pharmaceutical composition further comprising additional therapeutic agent(s) selected from warfarin, unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, hirudin, argatroban, aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, dipyridamol, droxicam, diclofenac, sulfinpyrazone, piroxicam, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, melagatran, ximelagatran, disulfatohirudin, tissue plasminogen activator, modified tissue plasminogen activator, anistreplase, urokinase, and streptokinase, or a combination thereof.
  • additional therapeutic agent(s) selected from warfarin, unfractionated heparin, low molecular weight heparin
  • the present invention provides a pharmaceutical composition wherein the additional therapeutic agent is an antihypertensive agent selected from ACE inhibitors, AT-I receptor antagonists, beta- adrenergic receptor antagonists, ETA receptor antagonists, dual ETA/AT- 1 receptor antagonists, renin inhibitors (alliskerin) and vasopepsidase inhibitors, an antiarrythmic agent selected from IKur inhibitors, an anticoagulant selected from thrombin inhibitors, antithrombin-III activators, heparin co-factor II activators, other factor XIa inhibitors, other kallikrein inhibitors, plasminogen activator inhibitor (PAI-I) antagonists, thrombin activatable fibrinolysis inhibitor (TAFI) inhibitors, factor Vila inhibitors, factor IXa inhibitors, and factor Xa inhibitors, or an antiplatelet agent selected from GPIIb/IIIa blockers, GP Ib/IX blockers, protease activated receptor 1
  • the present invention provides pharmaceutical composition, wherein the additional therapeutic agent(s) are an anti-platelet agent or a combination thereof.
  • the present invention provides a pharmaceutical composition, wherein the additional therapeutic agent is the antiplatelet agent clopidogrel.
  • the compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents.
  • administered in combination or “combination therapy” it is meant that the compound of the present invention and one or more additional therapeutic agents are administered concurrently to the mammal being treated.
  • each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.
  • Compounds that can be administered in combination with the compounds of the present invention include, but are not limited to, anticoagulants, anti-thrombin agents, anti-platelet agents, fibrinolytics, hypolipidemic agents, antihypertensive agents, and anti-ischemic agents.
  • anticoagulant agents include warfarin, heparin (either unfractionated heparin or any commercially available low molecular weight heparin, for example LOVENOXTM), synthetic pentasaccharide, direct acting thrombin inhibitors including hirudin and argatroban, as well as other factor Vila inhibitors, factor IXa inhibitors, factor Xa inhibitors (e.g., ArixtraTM, apixaban, rivaroxaban, LY-517717, DU-176b, DX-9065a, and those disclosed in WO 98/57951, WO 03/026652, WO 01/047919, and WO 00/076970), factor XIa inhibitors, and inhibitors of activated TAFI and PAI-I known in the art.
  • warfarin heparin (either unfractionated heparin or any commercially available low molecular weight heparin, for example LOVENOXTM)
  • synthetic pentasaccharide
  • anti-platelet agents denotes agents that inhibit platelet function, for example, by inhibiting the aggregation, adhesion or granule-content secretion of platelets.
  • agents include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as acetaminophen, aspirin, codeine, diclofenac, droxicam, fentaynl, ibuprofen, indomethacin, ketorolac, mefenamate, morphine, naproxen, phenacetin, piroxicam, sufentanyl, sulfinpyrazone, sulindac, and pharmaceutically acceptable salts or prodrugs thereof.
  • NSAIDS non-steroidal anti-inflammatory drugs
  • NSAIDS acetylsalicylic acid or ASA
  • piroxicam are preferred.
  • suitable platelet inhibitory agents include glycoprotein Ilb/IIIa antagonists (e.g., tirofiban, eptifibatide, abciximab, and integrelin), thromboxane-A2-receptor antagonists (e.g., ifetroban), thromboxane-A-synthetase inhibitors, phosphodiesterase-III (PDE-III) inhibitors (e.g., dipyridamole, cilostazol), and PDE-V inhibitors (such as sildenafil), protease-activated receptor 1 (PAR-I) antagonists (e.g., E-5555, SCH-530348, SCH-203099, SCH-529153 and SCH- 205831), and pharmaceutically acceptable salts or prodrugs thereof.
  • PAR-I protease-activated receptor 1
  • Suitable anti-platelet agents for use in combination with the compounds of the present invention, with or without aspirin, are ADP (adenosine diphosphate) receptor antagonists, preferably antagonists of the purinergic receptors P2Y1 and P2Y12J wrtn P2Y12 being even more preferred.
  • Preferred P2Y12 receptor antagonists include clopidogrel, ticlopidine, prasugrel, and AZD-6140, cangrelor, and pharmaceutically acceptable salts or prodrugs thereof.
  • Ticlopidine and clopidogrel are also preferred compounds since they are known to be more gentle than aspirin on the gastro-intestinal tract in use. Clopidogrel is an even more preferred agent.
  • a preferred example is a triple combination of a compound of the present invention, aspirin, and another anti-platelet agent.
  • the antiplatelet agent is clopidogrel or prasugrel, more preferably clopidogrel.
  • thrombin inhibitors denotes inhibitors of the serine protease thrombin.
  • various thrombin-mediated processes such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the secretion of platelet granule contents including serotonin) and/or fibrin formation are disrupted.
  • thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds.
  • Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin, argatroban, dabigatran, AZD-0837, and those disclosed in WO 98/37075 and WO 02/044145, and pharmaceutically acceptable salts and prodrugs thereof.
  • Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof.
  • hirudin includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin.
  • thrombolytic agents denotes agents that lyse blood clots (thrombi).
  • agents include tissue plasminogen activator (TPA, natural or recombinant) and modified forms thereof, anistreplase, urokinase, streptokinase, tenecteplase (TNK), lanoteplase (nPA), factor Vila inhibitors, thrombin inhibitors, inhibitors of factors IXa, Xa, and XIa, PAI-I inhibitors (i.e., inactivators of tissue plasminogen activator inhibitors), inhibitors of activated TAFI, alpha-2-antiplasmin inhibitors, and anisoylated plasminogen streptokinase activator complex, including pharmaceutically acceptable salts or prodrugs thereof.
  • TPA tissue plasminogen activator
  • TNK tenecteplase
  • nPA lanoteplase
  • factor Vila inhibitors thrombin inhibitors
  • anistreplase refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein.
  • urokinase as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase.
  • Suitable cholesterol/lipid lowering agents and lipid profile therapies for use in combination with the compounds of the present invention include HMG-CoA reductase inhibitors (e..g, pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, and other statins), low-density lipoprotein (LDL) receptor activity modulators (e.g., HOE-402, PCSK9 inhibitors), bile acid sequestrants (e.g., cholestyramine and colestipol), nicotinic acid or derivatives thereof (e.g., HMG-CoA reductase inhibitors (e..g, pravastatin, lovastatin, simvastatin, fluvastatin, atorvsatatin, rosuvastatin, and other statins), low-density lipoprotein (LDL) receptor activity modulators (e.g., HOE-402, PCSK9 inhibitors
  • GPRl 09B neuropeptidic acid receptor modulators
  • fenofibric acid derivatives e.g., gemfibrozil, clofibrate, fenofibrate and benzafibrate
  • PPAR peroxisome proliferator-activated receptors
  • PPARdelta modulators e.g., GW-501516
  • PPARgamma modulators e.g., rosiglitazone
  • compounds that have multiple functionality for modulating the activities of various combinations of PPARalpha, PPARgamma and PPARdelta, probucol or derivatives thereof e.g., AGI-1067
  • cholesterol absorption inhibitors and/or Niemann-Pick Cl- like transporter inhibitors e.g., ezetimibe
  • cholesterol ester transfer protein inhibitors e.g., CP-529414
  • the compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of thrombin, Factor Vila, IXa, Xa, XIa, and/or plasma kallikrein.
  • Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving thrombin, Factor Vila, IXa, Xa, XIa, and/or plasma kallikrein.
  • XIa for example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimentor that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound.
  • compounds according to the present invention could be used to test their effectiveness.
  • the compounds of the present invention may also be used in diagnostic assays involving thrombin, Factor Vila, IXa, Xa, XIa, and/or plasma kallikrein.
  • thrombin, Factor Vila, IXa, Xa XIa, and/or plasma kallikrein in an unknown sample could be determined by addition of the relevant chromogenic substrate, for example S2366 for Factor XIa, to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude Factor XIa was present.
  • Extremely potent and selective compounds of the present invention those having Kj values less than or equal to 0.001 ⁇ M against the target protease and greater than or equal to 0.1 ⁇ M against the other proteases, may also be used in diagnostic assays involving the quantitation of thrombin, Factor Vila, IXa, Xa, XIa, and/or plasma kallikrein in serum samples.
  • the amount of Factor Vila in serum samples could be determined by careful titration of protease activity in the presence of the relevant chromogenic substrate, S2366, with a potent and selective Factor Vila inhibitor of the present invention.
  • the present invention also encompasses an article of manufacture.
  • article of manufacture is intended to include, but not be limited to, kits and packages.
  • the article of manufacture of the present invention comprises: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition, comprises: a first therapeutic agent, comprising: a compound of the present invention or a pharmaceutically acceptable salt form thereof; and, (c) a package insert stating that the pharmaceutical composition can be used for the treatment of a thromboembolic and/or inflammatory disorder (as defined previously).
  • the package insert states that the pharmaceutical composition can be used in combination (as defined previously) with a second therapeutic agent to treat a thromboembolic and/or inflammatory disorder.
  • the article of manufacture can further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container. Located within the first and second containers means that the respective container holds the item within its boundaries.
  • the first container is a receptacle used to hold a pharmaceutical composition. This container can be for manufacturing, storing, shipping, and/or individual/bulk selling. First container is intended to cover a bottle, jar, vial, flask, syringe, tube (e.g., for a cream preparation), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product.
  • the second container is one used to hold the first container and, optionally, the package insert.
  • the second container include, but are not limited to, boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags), pouches, and sacks.
  • the package insert can be physically attached to the outside of the first container via tape, glue, staple, or another method of attachment, or it can rest inside the second container without any physical means of attachment to the first container.
  • the package insert is located on the outside of the second container. When located on the outside of the second container, it is preferable that the package insert is physically attached via tape, glue, staple, or another method of attachment.
  • the package insert is a label, tag, marker, etc. that recites information relating to the pharmaceutical composition located within the first container.
  • the information recited will usually be determined by the regulatory agency governing the area in which the article of manufacture is to be sold (e.g., the United States Food and Drug Administration).
  • the package insert specifically recites the indications for which the pharmaceutical composition has been approved.
  • the package insert may be made of any material on which a person can read information contained therein or thereon.
  • the package insert is a printable material (e.g., paper, plastic, cardboard, foil, adhesive-backed paper or plastic, etc.) on which the desired information has been formed (e.g., printed or applied).
  • a printable material e.g., paper, plastic, cardboard, foil, adhesive-backed paper or plastic, etc.
  • Solvent A 10% acetonitrile, 90% water, 0.1% trifluoroacetic acid.
  • Solvent B 90% acetonitrile, 10% water, 0.1% trifluoroacetic acid.
  • UV 220 nM.
  • N,O-Dimethylhydroxylamine hydrochloride (16.60 g, 170 mmol) and pyridine (34.4 mL, 425 mmol) in DCM (250 mL) and acetonitrile (50 mL) at 0 0 C, was added a solution of the acid chloride prepared above in DCM (100 mL), dropwise over 20 min. The resultant suspension was removed from the ice bath and was stirred at rt for 6 h.
  • Et 2 O (62.6 mL, 188 mmol), was added a solution of Intermediate 8A (34.6 g, 134 mmol) in Et 2 O (200 mL) at rt, dropwise via a canulla over 30 min. The resulting suspension was stirred at rt. Additional 3 M methylmagnesium iodide in Et 2 O (20 mL, 60 mmol) was added and the gray solution was stirred at rt for 5 h. The reaction was cooled to 0 0 C, then was carefully quenched with H 2 O. The thick mixture was acidified with IN HCl, then was extracted with Et 2 O (2x).
  • Oxalyl chloride (8.35 mL, 16.70 mmol) was added dropwise to a solution -+of 4-(4-bromophenyl)butanoic acid (2.03 g, 8.35 mmol) and DMF (0.030 mL, 0.398 mmol) in CH 2 Cl 2 (16 mL) at 25 0 C over 10 min.
  • the reaction mixture was stirred for 2 h, concentrated in vacuo and azeoptroped with toluene (2 x 25 mL).
  • the reaction mixture was concentrated in vacuo and purified by prep HPLC to yield the racemic macrocycle (105 mg).
  • the racemate was separated into peak 1 (30 mg) and Example 1 (30 mg) using with a Chiralcel OD-H (2.0 cm X 25 cm, 5 micron, Chiral Technologies, Inc.), 50% MeOH/EtOH (1 : 1)/ 50% Heptane, 20 mL/min flow rate, and uv detection at 220 nm.
  • Example 2 LC/MS (ESI) m/z 547.5 (M+H) + .
  • Example 3 (/?)-4-Methyl-2-(3-oxo-2,3-dihydro-lH-isoindol-5-ylamino)-7- (propane-2-sulfonyl)-4,ll-diaza-tricyclo[14.2.2.1 6 ' 10 ]henicosa- l(19),6,8,10(21),16(20),17-hexaene-3,12-dione trifluoroacetic acid salt
  • reaction mass was diluted with water extracted with ethyl acetate washed with water and brine, dried over sodium sulfate and concentrated.
  • the crude product was purified by preparative HPLC, followed by flash chromatography (1 to 20% MeOH/CH 2 Cl 2 gradient) to afford the 81 mg of the racemic macrocycle as a pale yellow solid.
  • the racemate 48 mg was separated via chiral chromatography (Chiralpak AD-H (20 x 250 mm) 90: 10 EtOH/heptane (20 mL/min) for 10 min to elute the less active enantiomer, followed by 100% MeOH for 20 min to elute the more active enantiomer).
  • the second peak was re-purified by preparative HPLC (CH 3 CN/H 2 O) to afford 23.4 mg of Example 3.
  • the crude product was purified by preparative HPLC, followed by recrystallization from methanol to afford 63 mg of the racemic macrocycle as a colorless solid.
  • the enantiomers were separated via chiral chromatography (Chiralpak AD-H (20 x 250 mm), 1: 1 MeOH/EtOH + 0.1% DEA (20 mL/min) for 15 min to elute the less active enantiomer, then 100% MeOH for 25 min to elute the more active enantiomer).
  • the second peak was purified by preparative HPLC (CH 3 CN/H 2 O) to afford 28 mg of Example 4.
  • Example 7 [(2R,5R)-17,20-Dimethyl-3,12-dioxo-2-(4-oxo-3,4-dihydro- quinazolin-6-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 ' jhenicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid
  • KF 8.70 g, 150 mmol
  • M-Bu 4 NCl 27.7 g, 100 mmol
  • Pd(dba) 2 290 mg, 0.5 mmol
  • 5-bromo-2-iodo-l-methylbenzene 15.55 g, 50 mmol
  • trimethyl(vinyl)silane 27 mL, 200 mmol
  • toluene 100 mL
  • tert-Butyldimethylsilyl chloride (1.483 g, 9.84 mmol) was added to a solution of 7C (2.05 g, 8.95 mmol) and imidazole (0.914 g, 13.42 mmol) in DCM (45 mL) and stirred for 4 h at rt.
  • the reaction was diluted with DCM (100 mL), washed with 0.5 M HCl (100 mL), brine, dried over Na 2 SO 4 and concentrated.
  • the crude oil was purified by column chromatography (0 to 40% EtOAc in Hexanes, 12O g column) to yield 7D (3.05 g, 8.88 mmol, 99 % yield) as a colorless oil.
  • a phosgene solution (20% in toluene, 58.5 mg, 0.118 mmol) was added dropwise to a solution of the yellow solid (66 mg, 0.118 mmol) in acetonitrilte (10 mL) at 0 0 C.
  • the cooling bath was removed and the cloudy mixture was stirred for 1 h at rt. Argon was bubbled though the solution and then 0.5 mL DBU was added.
  • the solution was added dropwise over 2 h to a solution of triethylamine (165 ⁇ L, 1.184 mmol) in CH 2 Cl 2 (30 mL) at 40 0 C.
  • the reaction mixture was concentrated and purified by prep HPLC (Phenom.
  • Example 8 [(2R,5R)-17,20-Dimethyl-3,12-dioxo-2-(l-oxo-l,2-dihydro- isoquinolin-7-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 ' jhenicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid ethyl ester
  • Example 8 (4 mg) and its diastereomer (2.5 mg).
  • Example 9 [(2R,5R)-17,20-Dimethyl-3,12-dioxo-2-(l-oxo-l,2-dihydro- isoquinolin-7-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 6 ' 10 ]henicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid
  • Example 9 LiOH (1.0 M, 2 mL) was added to a mixture of Example 8 and its diastereomer (40 mg) in THF (2 mL) and stirred for 2 h at rt.
  • the reaction mixture was concentrated and purified by HPLC (Phenom. Luna C18, 21.2x100 mm, 10 micron, flow rate 20 mL/min, A: H 2 OMeOH (9: 1), B: H 2 OMeOH (1:9), 0.1 %TFA, 20 to 100% B, 10 min gradient.) to yield Example 9 (15 mg) and its diastereomer (7 mg) as a white solid.
  • Example 10 [(2R,5R)-17,20-Dimethoxy-3,12-dioxo-2-(l-oxo-l,2-dihydro- isoquinolin-7-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 ' jhenicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid ethyl ester
  • the reaction mixture was diluted with H 2 O (200 mL) and extracted with Et 2 O (1 x 400 mL). The organic layer was washed with brine, dried over Na 2 SO 4 and concentrated. The crude product was purified by column chromatography (0 to 15% EtOAc in Hexanes, 40 g column) to yield 1OB (2.5 g, 7.29 mmol, 33.8 % yield) as a white solid.
  • Example 10 (30 mg, 0.049 mmol, 15.92 % yield) as a 2.6: 1 mixture of diastereomers.
  • 1 H NMR 400 MHz, CD 3 OD
  • Example 11 [(2R,5R)-17,20-Dimethoxy-3,12-dioxo-2-(l-oxo-l,2-dihydro- isoquinolin-7-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 ' jhenicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid
  • Example 12 [(2R,5R)-17,20-Dimethoxy-3,12-dioxo-2-(4-oxo-3,4-dihydro- quinazolin-6-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 ' Jhenicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid ethyl ester
  • Example 12 25 mg, 0.041 mmol, 20.59 % yield
  • 1 H NMR 400 MHz, CD 3 OD
  • Example 13 [(2R,5R)-17,20-Dimethoxy-3,12-dioxo-2-(4-oxo-3,4-dihydro- quinazolin-6-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 6 ' 10 ]henicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid
  • Example 14 4,17,20-Trimethyl-2-(l-oxo-l,2-dihydro-isoquinolin-7-ylamino)-13- oxa-4,ll-diaza-tricyclo[14.2.2.1 6 ' 10 ]henicosa-l(19),6,8,10(21),16(20),17-hexaene- 3,12-dione
  • 15A (66.4 mg, 0.409 mmol) and 8A (150 mg, 0.409 mmol) were coupled using triethylamine, l-hydroxy-7-azabenzotriazole, and l-(3- (dimethylamino)propyl)-ethyl-carbodiimide HCl and purified by flash chromatography (0 to 20% MeOH in CH 2 Cl 2 ) to yield 15B (150 mg, 0.294 mmol, 71.8 % yield) as a yellow solid.
  • MS (ESI) m/z 511.4 (M+H) + .
  • Example 17 (36 mg, 0.069 mmol, 12.60 % yield) and diasteromer 2 (14 mg, 0.027 mmol, 4.90 % yield) as a white solid.
  • MS (ESI) m/z 525.5 (M+H) + .
  • Example 18 (2R,15R)-7-Cyclopropanesulfonyl-17-ethyl-4,15-dimethyl-2-(l-oxo- l,2-dihydro-isoquinolin-7-ylamino)-13-oxa-4,ll-diaza- tricyclo[14.2.2.1 6 ' 10 ]henicosa-l(19),6,8,10(21),16(20),17-hexaene-3,12-dione
  • Example 19 [(2R,5R,15R)-17-Ethyl-15-methyl-3,12-dioxo-2-(l-oxo-l,2-dihydro- isoquinolin-7-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 6 ' 10 ]henicosa- l(19),6,8,10(21),16(20),17-hexaen-5-yl]-acetic acid ethyl ester
  • Example 20 LiOH (2 mL, 1.0 M, aq) was added to a solution of Example 19 (30 mg, 0.050 mmol) in THF (2 mL) and stirred for 1 h at rt. HCl (2 mL, 1.0 M, aq) was added and the reaction mixture was concentrated. Purification by prep HPLC yielded Example 20 (21 mg, 0.037 mmol, 73.5 % yield) as a white solid. MS (ESI) m/z 569.2 (M+H) + .
  • Example 21 (2R,15R)-7-Methoxymethyl-4,15,17-trimethyl-2-(l-oxo-l,2-dihydro- isoquinolin-7-ylamino)-13-oxa-4,ll-diaza-tricyclo[14.2.2.1 6 ' 10 ]henicosa- l(19),6,8,10(21),16(20),17-hexaene-3,12-dione
  • the reaction mixture was heated at 50 0 C for 4 h and then quenched with sat. NaHC ⁇ 3 and extracted with DCM (3x300OmL) and concentrated to an oily residue.
  • the residue was dissolved in MeOH (50OmL) and THF (20OmL) and treated with an aqueous solution of K 2 CO 3 (20OmL). After stirring for 30 min the mixture was concentrated to one quarter volume and diluted with brine (20OmL).
  • the resulting mixture was cooled to 0 0 C and adjusted to pH 4-5 with IN KHSO 4 and extracted with ethyl acetate (3x200 mL).
  • BoC 2 O (0.539 mL, 2.319 mmol) was added to a solution of 21D (960 mg, 2.209 mmol) and TEA (0.616 mL, 4.42 mmol) in CH 2 Cl 2 (20 mL) and stirred at rt overnight.
  • the reaction was diluted with CH 2 Cl 2 (80 mL), washed with 0.1 M HCl, sat'd NaHC ⁇ 3 and brine (50 mL each), dried over Na 2 SO 4 and concentrated.
  • TBAF (4.42 mL, 4.42 mmol) was added to a solutin of the crude product in THF (20 mL) and stirred for 1 h.
  • Methanesulfonic anhydride (529 mg, 3.04 mmol) was added in one portion to a solution of 21E (600 mg, 2.025 mmol) and pyridine (0.409 mL, 5.06 mmol) in THF (20 mL) and stirred for 2 h. Lithium bromide (352 mg, 4.05 mmol) was added and the reaction mixture was stirred for 3 h. The mixture was diluted with EtOAc (100 mL), washed with water and brine (50 mL each), dried over Na 2 SO 4 and concentrated.
  • Example 23 25 mg, 0.042 mmol, 8.54 % yield
  • R,R-Welko-O 1 column (21.1 mm X 250 mm, 10 micron, Regis Technologies, Inc.), 80% MeOH/EtOH (1 : 1)/ 20% Heptane, 20 mL/min flow rate, and uv detection at 220 nm.
  • Example 24 The mixture was separated into diastereomer 1 (55 mg, 0.091 mmol, 11.44 % yield) and Example 24 (65 mg, 0.107 mmol, 13.52 % yield) using a R,R-Welko-O 1 column (21.1 mm X 250 mm, 10 micron, Regis Technologies, Inc.), 40% MeOH/EtOH (1 : 1)/ 60% Heptane, 20 mL/min flow rate, and uv detection at 220 nm. Characterization for Example 24: MS (ESI) m/z 604.4 (M+H) + .
  • Example 25 (2R,15R)-7-(2-Ethyl-2H-pyrazol-3-yl)-4,l 5,17-trimethyl-2-(l-oxo- l,2-dihydro-isoquinolin-7-ylamino)-13-oxa-4,ll-diaza- tricyclo[14.2.2.1 6 ' 10 ]henicosa-l(19),6,8,10(21),16(20),17-hexaene-3,12-dione
  • the mixture of diastereomers was separated into diastereomer 1 (32 mg, 0.053 mmol, 10.56 % yield) and Example 25 (32 mg, 0.053 mmol, 10.56 % yield) using a R,R-Welko-O 1 column (21.1 mm X 250 mm, 10 micron, Regis Technologies, Inc.), 40% MeOH/EtOH (1 : 1)/ 60% Heptane, 20 mL/min flow rate, and uv detection at 254 nm. MS (ESI) mk 605.4 (M+H) + .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
EP07869479A 2006-12-20 2007-12-19 Macrocyclic factor viia inhibitors useful as anticoagulants Withdrawn EP2102176A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87086406P 2006-12-20 2006-12-20
US98446007P 2007-11-01 2007-11-01
PCT/US2007/088032 WO2008079836A2 (en) 2006-12-20 2007-12-19 Macrocyclic factor viia inhibitors useful as anticoagulants

Publications (1)

Publication Number Publication Date
EP2102176A2 true EP2102176A2 (en) 2009-09-23

Family

ID=39430763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07869479A Withdrawn EP2102176A2 (en) 2006-12-20 2007-12-19 Macrocyclic factor viia inhibitors useful as anticoagulants

Country Status (12)

Country Link
US (1) US8420830B2 (enExample)
EP (1) EP2102176A2 (enExample)
JP (1) JP2010514681A (enExample)
AR (1) AR064471A1 (enExample)
AU (1) AU2007337025A1 (enExample)
CA (1) CA2673598A1 (enExample)
CL (1) CL2007003718A1 (enExample)
MX (1) MX2009006689A (enExample)
NO (1) NO20092279L (enExample)
PE (1) PE20081775A1 (enExample)
TW (1) TW200836735A (enExample)
WO (1) WO2008079836A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631784A (zh) 2006-12-20 2010-01-20 百时美施贵宝公司 用作抗凝血药的二环内酰胺凝血因子viia抑制剂
PH12012501153A1 (en) * 2009-12-08 2012-10-22 Boehringer Ingelheim Int Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
PH12012501589A1 (en) * 2010-02-11 2012-10-22 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
CN102993065B (zh) * 2011-09-13 2015-07-29 中国科学院上海药物研究所 含手性叔丁基亚磺酰基的α-芳基氨基酸酯类化合物、其制备方法及用途
HRP20170784T8 (hr) 2011-10-14 2018-05-18 Bristol-Myers Squibb Company Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora
EP2797881B1 (en) * 2011-12-27 2018-11-14 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
EP2858977A1 (en) 2012-06-08 2015-04-15 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
CN104507924B (zh) * 2012-08-03 2018-01-23 百时美施贵宝公司 二氢吡啶酮p1作为凝血因子xia抑制剂
WO2014022766A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
US9657006B2 (en) 2013-06-13 2017-05-23 Bristol-Myers Squibb Company Macrocyclic factor VIIa inhibitors
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (enExample) 2014-01-31 2018-03-10
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3072943B1 (en) 2015-03-26 2018-05-02 Idemitsu Kosan Co., Ltd. Dibenzofuran/carbazole-substituted benzonitriles
CN114874222B (zh) * 2015-07-29 2025-06-06 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5866542A (en) 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
HUP0400651A2 (hu) * 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
WO2003011222A2 (en) 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
US7122559B2 (en) * 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
WO2004072102A2 (en) * 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Benzene acetamide compounds useful as serine protease inhibitors
ATE479676T1 (de) * 2005-01-10 2010-09-15 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
JP2008538102A (ja) * 2005-03-03 2008-10-09 ザ バーナム インスティテュート フォー メディカル リサーチ バーチャルドッキングアプローチを適用したプロテインキナーゼｂ阻害剤のスクリーニング方法並びにそれにより見出された化合物及び組成物
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
TW200745062A (en) * 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
US8044242B2 (en) 2006-03-09 2011-10-25 Bristol-Myers Squibb Company 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants
CN101631784A (zh) 2006-12-20 2010-01-20 百时美施贵宝公司 用作抗凝血药的二环内酰胺凝血因子viia抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008079836A2 *

Also Published As

Publication number Publication date
NO20092279L (no) 2009-08-31
AU2007337025A1 (en) 2008-07-03
US8420830B2 (en) 2013-04-16
JP2010514681A (ja) 2010-05-06
WO2008079836A2 (en) 2008-07-03
CA2673598A1 (en) 2008-07-03
WO2008079836A4 (en) 2009-03-12
US20100113488A1 (en) 2010-05-06
CL2007003718A1 (es) 2008-07-11
WO2008079836A3 (en) 2009-01-15
AR064471A1 (es) 2009-04-01
MX2009006689A (es) 2009-06-30
TW200836735A (en) 2008-09-16
PE20081775A1 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
US8420830B2 (en) Macrocyclic factor VIIa inhibitors useful as anticoagulants
US10208021B2 (en) Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
US9108981B2 (en) Cyclic P1 linkers as factor XIa inhibitors
EP2978751B1 (en) Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
EP2265601B1 (en) Pyridazine derivatives as factor xia inhibitors
EP3189047B1 (en) Diamide macrocycles that are fxia inhibitors
US8039506B2 (en) Bicyclic lactam factor VIIa inhibitors useful as anticoagulants
EP3099688A1 (en) Macrocyclic factor xia inhibitors condensed with heterocycles
NZ568715A (en) Macrocyclic factor VIIA inhibitors useful as unticoagulants
EP3868753B1 (en) Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group
CN101611019A (zh) 可用作抗凝血药的大环凝血因子Ⅶa抑制剂
NZ624874B2 (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090624

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20090624

17Q First examination report despatched

Effective date: 20110519

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150311

INTG Intention to grant announced

Effective date: 20150323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150804